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ABSTRACT 
 
Asthma affects nearly two and a half million people in Canada (1).  In 
Saskatchewan, the prevalence of asthma has increased across all age groups since 1981.  
Current literature indicates that the purchase of all asthma medications increased in the 
last 20 years both province and nationwide (2;3).  Since the early 1990s, the Canadian 
Consensus Guidelines (CCG) for the treatment of asthma recommended increasing the 
use of inhaled corticosteroids as a mainstay for controlling asthma symptoms.  The CCG 
have also encouraged decreasing the use of short-acting, inhaled beta2-agonist 
medication.   
The objective of this descriptive epidemiological study was to investigate asthma 
medication prescribing at the individual level among physician-diagnosed asthma 
patients, aged 0 to 64 years, in Saskatchewan from January 1, 1991 to December 31, 
2000.  Saskatchewan residents covered under the provincial health insurance plan who 
received a physician’s diagnosis of asthma, identified each calendar year, were included 
in the study (296,430 asthma patients in total).   
Nearly 80.0% of this asthma population purchased at least one asthma 
medication in each calendar year. From 1991 to 2000, users and the mean number of 
prescriptions of short-acting beta2-agonists decreased slightly. The proportion of users 
and mean number prescriptions per year of inhaled corticosteroids increased. The 
highest mean numbers of prescriptions and users of inhaled corticosteroids were among 
the 0-4 year olds.   
Short-acting beta2-agonists, inhaled corticosteroids, and oral corticosteroids were 
the most popular medications.  Users of theophyllines and cromoglycates decreased. The 
15-34 year old males showed the greatest “inappropriate” use as high users of short-
acting beta2-agonists and low users of inhaled corticosteroids.   
There was increasing compliance with the CCG over the ten years. The 
combination of beta2-agonists with inhaled corticosteroids usurped beta2-agonist 
monotherapy as the most popular form of asthma therapy by the year 2000.  Users of 
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combination therapy increased from 19% to 38.7%, while users of beta2-agonists alone 
decreased from 34.5% to 23.1%.   
From 1996 to 2000, the monthly number of both short-acting β2-agonists and 
inhaled corticosteroids prescriptions decreased for all users in July and August.  Peak 
increases in the number of short-acting beta2-agonist prescriptions, for children under 
15, occurred in September.  For adults, peak increases occurred in December for both 
medications.   
These study results will enhance the understanding of asthma medication use 
among children and adults and will help healthcare professionals develop new treatment 
programs for the management of asthma. 
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1.  INTRODUCTION 
 
1.1  Introduction and Study Rationale 
 
Asthma is a hyper-responsive inflammatory process in which airways are 
narrowed, through inflammation, bronchoconstriction, and excessive production of 
mucus.  This is usually in response to at least one of many triggering factors.  Asthma is 
a common disease in Canada with nearly 2.5 million affected persons nationwide (1).  A 
definition of asthma established at the Canadian Asthma Consensus Conference in 1999 
is as follows: 
“Asthma is characterized by paroxysmal or persistent symptoms such as 
dyspnea, chest tightness, wheezing, sputum production and cough 
associated with variable airflow limitation and a variable degree of hyper-
responsiveness of airways to endogenous or exogenous stimuli.” (4)  
During a typical asthma episode the muscles around the bronchi of the lungs 
contract, the membrane lining the inside of the bronchi becomes inflamed, and excess 
mucus in the air passages is secreted forming mucus plugs which further restrict air flow 
(5).   
Although asthma occurs in adults, prevalence decreases with age (1).  Children 
and young adults are the principal sufferers of the disease (1).  Over the last 20 years the 
prevalence, incidence, hospitalization rates, and mortality rates for asthma have 
increased in Canada (3).  Nationally, the prevalence of physician-diagnosed asthma 
among Canadians aged four and older in 1994/95 was 7% (6).  In 1996/97 the 
prevalence was 8%, and in 1998/99 it had increased to 9% (6).  Statistics Canada found 
in 1998/99 that males aged 4 to 14 were more likely to be diagnosed with asthma than 
females but, for most other age groups, females were more likely to receive an asthma 
diagnosis (6). 
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One of the most recent studies of the prevalence of asthma in Saskatchewan in 
1998 found that for asthma cases identified by first physician visit each year, the 
prevalence of asthma in the provincial population was 8.1% among children aged 0 to 4 
years, 5.9% for those 5 to 14 years, 3.5% for those 15 to 34 years, and 2.7% for those 35 
to 64 years (2;7).  For children aged 0 to 14 years, prevalence was greater for males than 
for females. For those between the ages of 15 and 64, the prevalence was greater for 
females than for males (7). In Saskatchewan, the prevalence of asthma showed a trend of 
increase across all age groups from 1981 to 1996 until 1997 and 1998 when there was a 
period of stability and even decline (2;7). 
As well as being indirectly costly and limiting individual quality of life, asthma 
is also directly expensive to the entire Canadian population.  The estimated healthcare 
cost (including drugs, physician care, hospital care, and research) of chronic bronchitis, 
emphysema, and asthma in 1993 was $1.33 billion (CAD).  It is one of Canada’s most 
costly diseases ranking third after cardiovascular diseases and mental health disorders 
(1;8).   
Although a recent review of economic studies in Canada, Australia, and the U.K. 
showed that there is wide variation in the measure of the “economic burden” of asthma 
(9), it can be seen across analyses that the cost of asthma is universally high. In a meta-
analysis where the economic burden of asthma was defined as hospitalizations due to 
non-compliance with prescribed medication regimens, researchers concluded that the 
cost of asthma was $1,018 million (CAD) per year (10).        
The treatment of asthma through drug management is a major component of the 
direct healthcare costs and management of asthma.  The recommended “continuum 
approach,” first established in 1996 by the Canadian Asthma Consensus Group (CACG) 
(11), as seen in Figure 1-1, states that persons with very mild asthma are typically 
managed with an “as-needed” β2-agonist drug for symptom relief or before exercise or 
other anticipated trigger (12). If the β2-agonist is needed more than three times per week, 
or if lung function is abnormal, an inhaled corticosteroid therapy is started.  Those with 
moderate asthma are often prescribed a maintenance therapy that involves inhaled 
corticosteroids in addition to β2-agonist rescue medication for symptom relief. An 
additional controller therapy may be added at the moderate severity level depending on 
 
 
3
reassessment.  Severe asthma can include daily maintenance therapy with inhaled 
corticosteroids and daily maintenance with additional controller therapy such as a long-
acting, inhaled β2-agonist or anti-leukotrienes (if the person cannot or will not use the 
inhaled corticosteroid treatment) or oral glucocorticosteroids or other controller 
therapies.  Again, this is in addition to short-acting β2-agonist rescue medication for 
symptom relief (4;12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1  Continuum of asthma management.  Adapted from Asthma Guidelines 
Update, 2001 (12)  
 
Research has shown that when short-acting beta2-agonist rescue medication is 
relied upon, for those with moderate to severe asthma, the condition is worsened [with 
increased hyperresponsiveness of the airways (13), remodeling of airway smooth 
muscle, and increased production of mediating cells which motivate an inflammatory 
response in the airways and mucus production (14)], and the need for rescue medication 
is increased.  Thus begins a negative cycle of worsening asthma with an ever-increasing 
demand for reliever medication. 
1000 2000 500 0
Moderately 
Severe 
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To understand the epidemiology of asthma and the health care utilization patterns 
of persons diagnosed with asthma in Saskatchewan, it is useful to observe and record the 
drug treatment regimens sought by persons with asthma.  It is logical to suppose that an 
increase in the prevalence of asthma will be followed by an increase in the receipt of 
treatment and consequent purchase of asthma medications.   
An appreciation of the treatment patterns, both real and those recommended by 
the CACG, will be helpful in managing the role of pharmacotherapy in the treatment of 
asthma in Saskatchewan.  This information may contribute to the determination of 
appropriate and effective targeted strategies for treatment and asthma education needs in 
the province. 
 
 1.2  Statement of the Problem 
The majority of research into asthma treatment has been of an ecological nature.  
Few studies have examined the development of asthma medication purchasing at the 
individual level with consideration of the historical context (i.e., beta2-agonist 
medication having been linked to mortality epidemics in the past) and the Canadian 
Consensus Guidelines (CCG) for the treatment of asthma (since their inception to the 
present) that may have influenced medication, research, education, and behaviour 
changes over time.  
 
1.3  Purpose of the Study 
The purpose of this study is to examine the current trends in the use of asthma 
medication by persons with physician-diagnosed asthma in the Province of 
Saskatchewan over the last decade.  This information provides insight into the 
prescribing and drug treatment trends associated with national practice and management 
guidelines for asthma.  As pharmacological treatment is used to measure asthma 
severity, the results of this study may make some inferences about that aspect of the 
disease, as well as asthma prevalence in Saskatchewan.   
The data was collected at the level of the individual which improved the 
precision of the associations between groups (by age, gender, region, medication group, 
etc.) to medication purchasing patterns over time.  This level of analysis advances our 
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understanding of the unique characteristics of persons with physician-diagnosed asthma 
and their medication use. 
 
1.4  Statement of Research Questions  
This thesis project is an analysis of data from the Physician Services Database 
and Saskatchewan Outpatient Prescription Drug Plan Database from January 1, 1991 to 
December 31, 2000.  This analysis addresses the following research questions: 
 
1) What is the variation in proportion of users of each drug for the treatment of 
asthma by age, sex, and region per year and in the mean number of asthma 
medications per person by age and sex per year from January 1, 1991 to 
December 31, 2000? 
 
2) What are the specific combinations of asthma medication used among persons 
with physician-diagnosed asthma by age and sex for the period of January 1, 
1991 to December 31, 2000?  
 
3) What is the variation in the monthly age-sex specific, short-acting inhaled ß2-
adrenergic agonist and inhaled corticosteroid use for the years 1996 to 2000? 
 
1.5  Significance of the Study  
The results of this study further the understanding of the epidemiology of 
asthma, provide useful information to health care workers in the treatment of asthma, 
and assist in the development of public policy related to the provision of health services 
for the Saskatchewan population. 
This project cannot be generalized to populations that are greatly different from 
the Province of Saskatchewan with its particular set of population characteristics, 
including the structure of health insurance coverage.  The Physician Services and 
Outpatient Prescription Services databases captured almost all of the information 
pertinent to this study for the provincially-covered population of Saskatchewan.  These 
databases can be electronically linked using individual Health Services Numbers.  
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2.  BACKGROUND INFORMATION AND LITERATURE REVIEW 
An overview of asthma itself (defining characteristics, pathophysiology, and 
epidemiology), the management of asthma, and the special circumstances surrounding 
the pharmacological treatment of the disease is presented in this section.  The 
background information will provide a context for this research study in attempting to 
understand the purchase of asthma medications by particular population characteristics. 
 
2.1  Background Information 
2.1.1  Pathophysiology 
Asthma is characterized by two major processes: inflammation of the airways, 
and bronchoconstriction.  The mechanisms of an asthma attack include contraction of 
the bronchi, inflammation of the membrane lining, and overproduction of mucus in the 
bronchioles. At the cellular level during an asthma attack, mast and eosinophil cells are 
excited, often in response to a “trigger” or allergen in the system, and substances 
including histamines and leukotrienes are released into the system (4).  This response 
contributes to the narrowing of the airways.   Common triggers include exposure to dust, 
pollen, cold air, and physical exertion (4).   An asthma attack can also occur as a 
response to an emotional stimulus, aspirin (and other drugs), and certain foods (4). 
To date, the pathogenesis of asthma is not entirely understood.  While much has 
been learned about the triggers, outcomes of asthma attacks, and the role that drug 
treatment plays in the mediation of asthmatic episodes, the specific cause (or causes) of 
these episodes is not certain.  In response to a trigger, excessive mucus accumulates and 
plugs the airways, inflammation occurs, and the presence of excess blood in the vessels 
that serve the lungs may also present.  
Mediators such as histamines, prostaglandins, leukotrienes, and chemotactic 
factors are released from lung cells (mast cells, eosinophils, T-lymphocytes, etc.) with 
an aim to rid the airways of a foreign agent(s).  However, for a person with asthma, the 
response to a trigger or irritant is in excess of what is normally seen and the result is 
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significantly reduced airflow.  These mediators initiate and prolong the asthmatic 
episode until treatment is applied to halt and reverse the effect of this systemic response. 
 
2.1.2  Symptoms 
Wheezing, coughing, chest tightness, shortness of breath, and the coughing of 
mucus or phlegm are common manifestations of an asthmatic episode (4).   Mild attacks 
may include a chronic dry cough while severe episodes can include fatigue, sudden 
drops in blood pressure upon inhalation, disappearance of breath sounds, and cyanosis.  
The frequency of attacks varies widely in the asthmatic population from seldom and 
brief to chronic and persistent.  Asthmatic episodes can occur at night during a period of 
sleep when bronchial reactivity seems inordinately sensitive.  Nocturnal symptoms are 
often taken as a sign of poor asthma control. 
 
2.1.3  Pharmacological treatment of asthma 
The CCG for asthma propose the pharmacological management of asthma follow 
the algorithm of a continuum as seen in Figure 1-1 (page 3) (12).  Medications are to be 
used at a minimal effective dose only after, and with ongoing consideration of, 
environmental control of asthma triggers and factors (12).  Each asthma patient is to be 
managed on a individual basis and should be encouraged to monitor and modify their 
own treatment if, and when, their disease worsens quickly (12).  The treatment of asthma 
is aimed at reducing and/or eliminating the respiratory symptoms of the disease and 
restoring normal lung function.  Through pharmacotherapy this is often achieved 
through two types of asthma medications: relievers, and controllers (Table 2-1).     
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Table 2-1  Asthma medications by their generic and brand names 
RELIEVERS 
(for intermittent symptoms) 
GENERIC NAME BRAND NAME 
Sympathomimetic (adrenergic) agents  (β2-agonists) 
Fenoterol Hydrobromide Berotec 
Orciprenaline SO4 Alti/Apo-Orciprenaline, Alupent, Orcipren 
Salbutamol SO4 
Airomir, Alti-Salbutalmol, Apo-Salvent, 
Asmavent, Dom-Salbutamol, Gen-Salbutamol, 
Med-Salbutamol,  Novo-Salmol, Nu-
Salbutamol, Pms-Salbutamol, Rho-
Salbutamol,Ventodisk, Ventolin   
Terbutaline SO4 Bricanyl 
Isoproterenol Isuprel 
Procaterol Adrenaline 
Antispasmolytics 
Ipratroprium Bromide 
Atrovent, Apo/Gen-Ipratropium /Novo/Nu/ 
Pms  
CONTROLLERS 
(for maintenance therapy) 
GENERIC NAME BRAND NAME 
Corticosteroids 
Beclomethasone Dipropionate Beclodisk, Becloforte, Beclovent, Vanceril  
Budesonide Pulmicort 
Fluticasone Propionate Bronalide, Flovent  
Flunisolide Flunisolide 
Triamcinolone  Aristocort, Azmacort, Kenalog, Triamcine 
Prednisone 
Apo-Prednisone, Deltasone, Novo-Prednisone, 
Prednisone, Winpred 
Predinsolone Sodium Phosphate Pediapred 
Long-acting Inhaled β2-agonists 
Salmeterol Xinafoate Serevent 
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Formoterol Fumarate Foradil, Oxese 
Leukotriene Modifiers 
Zafirlukast Accolate 
Montelukast Singulair 
Respiratory Smooth Muscle Relaxants (Spasmolytics) 
Oxtriphylline 
Apo-Oxtriphylline, Choledyl, Novo-Triphyl, 
Rouphylline 
Theophylline 
Apo-Theo-La, Novo-Theophyl, Slo-Bid, 
Theolair, Theochron, Theo-Dur, Theo-SR, 
Uniphyl 
Unclassified Therapeutic Agents 
Sodium Cromoglycate 
Gen-Cromoglycate, Intal, Nalcrom, Apo/ 
Novo /Nu-Cromolyn,  
Ketotifen Fumarate Apo/Novo/Nu/Pms-Ketotifen, Zaditen 
Nedocromil SO4 Tilade 
 
 2.1.3.1  Reliever medication  
Reliever medications include the bronchodilators (predominantly short-acting 
inhaled β2-agonists) which bring immediate, fast-acting relief from the brochospasm 
associated with an asthma attack by relaxing the muscles around the bronchi.  Their 
effect is usually of a short duration although some longer acting β2-agonists can bring 
relief for up to 12 hours, as they are lipophilic, meaning that the drug with remain in fat 
tissue for extended periods releasing slowly into the system (15).  Other reliever 
medications include ipratropium bromide, which is considered to be less effective than 
short-acting β2-agonists but appropriate for persons showing low tolerance for β2-
agonist drugs (4).  
The dilemma regarding the use of short-acting β2-agonist medication for the 
control of asthma is that although these medications provide the best (and often only) 
available treatment for the immediate relief of asthma symptoms, some research 
suggests they may become ineffective after increased and extended dosing (16).  Worse 
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yet, research also suggests that in some circumstances the use of short-acting β2-agonists 
may intensify the disease (17). 
 
 2.1.3.2  Controller medication  
Both anti-inflammatory medications, steroidal (e.g., oral and inhaled 
glucocorticosteroids, oral leukotriene-receptor antagonists) and non-steroidal (e.g., 
inhaled cromoglycate and oral nedocromil), are used to maintain control of asthma. 
Corticosteroids provide relief from the disease by reducing both the inflammation of the 
airways, and the production of mucus.  The effects of these drugs are gradual and as 
such they are prescribed for use as long-term maintenance therapy for the control of 
asthma (4).   These medications address airway inflammation but do not relieve the 
immediate acute symptoms during an asthma attack.  Long-acting β2-agonists also fall 
into the category of controller medications as they provide prolonged relief from 
bronchial constriction (up to 12 hours).  
A principal side-effect associated with anti-inflammatory drug use is mild fungal 
infection of the mouth and throat (candidiasis). There is also an additional concern that 
growth retardation may result as a side effect of the treatment for children using 
corticosteroid drugs in high doses or in oral form over long periods of time (18).  A 
reduction in bone mineral density is a side-effect associated with oral corticosteroid use 
that is especially concerning for very old and very young persons with asthma (18). 
 
2.1.4  The management of asthma 
The CACG favour the “continuum approach” (Figure 1-1, page 3) (12) for the 
management of asthma as opposed to the step-wise approach endorsed by the National 
Institutes of Health in the United States (19).  The CCG for the appropriate treatment of 
asthma aligns a pharmacological regimen with the corresponding symptom 
characteristics and severity of the individual’s disease.  It also stresses the importance of 
education and environmental control in the management of asthma.  The CCG proposes 
an algorithm for the management of asthma that focuses on four main areas: diagnosis; 
achievement of control; maintenance of control; and, regular follow-up.  
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Current recommendations state that if a short-acting β2-agonist is needed more 
than 3 times a week, 400-1000 µg per day of beclomethasone-chlorofluorocarbon (BDP-
CFC) or its equivalent should be initiated (4;12), this is 200-1000 µg per day for 
children (4).  For children requiring at least 400µg per day of BDP-CFC, a steroid 
sparing medication such as salmeterol or montelukast should be added (20).  This 
represents the next phase in the continuum where symptom characteristics are 
considered “persistent” and the severity of asthma is rated “moderate” or worse.  When 
acceptable control is achieved, the goal of management is to establish the minimal 
amount of medication needed to maintain symptom control. 
Regular follow-up and re-evaluation of the treatment regimen is critical to 
asthma management.  This includes the creation of an action plan, ongoing evaluation of 
environmental control, confirmation that compliance with medication is maintained, 
continuing education and, if required, specialist referral (4). 
 
2.2  Literature Review 
2.2.1  International research history 
  In the 1960s, 1970s, and 1980s there were epidemics of asthma mortalities 
reported first in six countries and then specifically in New Zealand (21).  In the many 
studies that followed, the epidemics were found to be most strongly associated with 
isoprenaline forte and fenoterol (21), which have been described as having “the 
distinction of being high-dose, poorly selective full agonists with relatively greater 
cardiac side effects.” (22) 
Research by Stolley in 1972 attempted to track the time-trend data to better 
understand the relationship between isoprenaline forte and asthma mortality.  In six of 
the eight countries in which the drug was released there was a strong association 
between the drug and asthma deaths.  In the two remaining countries, the drug was 
introduced late in the asthma season resulting in low sales; thus, they did not experience 
the mortality epidemics of the other countries.  There were no mortality epidemics in the 
U.S., Canada, Sweden, or West Germany where isoprenaline forte was not licensed (22). 
Studies conducted in Australia and the USA examined trends in the use of 
asthma medications in the 1970s, early to mid 1980s, and early 1990s (23-25). These 
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studies indicated that since the 1970s, there has been an overall increase in the 
proportion of asthma prescriptions purchased.  They also show that there is greater use 
of bronchodilators over inhaled corticosteroids.  Although trends in the use of 
bronchodilators were high in these studies, conclusions regarding the characteristics of 
users were not possible because of the ecological nature of the data.  
 
2.2.2  Canadian research history 
Given the international results, a nested case-control study by Spitzer et al. was 
conducted from 1978 to 1987 and published in 1992 in Saskatchewan to investigate the 
relationship between death and the use of fenoterol and salbutamol beta2-agonist 
brochodilators.  The study revealed high odds ratios with mortality and fenoterol use 
(OR=6.1, 95% C.I. 3.1 to 12.2) and salbutamol use (OR=4.1, 95% C.I. 2.1 to 8.0) (17).  
The odds ratios increased with additional doses of these medications.  The subjects using 
fenoterol regularly, 4 times daily with additional rescue doses as-needed, had worse 
outcomes at the end of the trial as compared to those who used the medication on an as-
needed basis only.  Explanations for the increase in risk included the hypothesis that 
short-acting β2-agonists may be responsible for worsening the disease’s severity and, 
therefore, the risk of death and near death. 
In a study by Habbick et al. investigating the trends in asthma-related medication 
use between 1989 and 1993 in the Saskatchewan population aged 5 to 54 years, the 
mean number of prescriptions per person decreased for all drugs to treat asthma (26).  
From 1989 to 1993, inhaled β2-agonists decreased from 4.35 to 3.05 mean prescriptions 
per year and inhaled corticosteroids decreased from 2.98 to 2.25 (26). The amount of 
fenoterol and inhaled salbutamol bronchodilators dispensed per person decreased by 
40% and 58%, respectively while the amount of inhaled corticosteroid increased by 35% 
in 1989 to 1992 and then declined slightly in 1993.  The authors offered as explanation 
the possibility that the observed changes in the use of these drugs may have been related 
to the awareness among health care workers of studies relating use of short-acting β2-
agonists to asthma deaths and near deaths.  Since the analysis was based on aggregated 
data and not on individual level data, the appropriateness of an individual’s dosage or 
coincident drug use could not investigated. 
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Later, serious criticism was brought against these two Canadian studies because 
of the disparity in potency between fenoterol, being the much stronger, and salbutamol 
(albuterol) (21;27).  The criticisms of the Spitzer et al. study extended to the 
methodology, but more importantly evidence that questioned a simple relationship 
between the use of beta2-agonists and death emerged with the absence of mortality 
epidemics in countries where short-acting, beta2-agonist purchases (excluding fenoterol 
and isoprenaline forte) increased rapidly (21).  Upon reanalysis of the Spitzer et al. 
study, it was found that excessive dosing of beta2-agonists was, in fact, the risk 
associated with death and near-death (27). 
   
2.2.3  Current Canadian research 
 2.2.3.1  Use of asthma medications 
In a recent study by Lynd et al., researchers performed a retrospective 
longitudinal analysis on three years of prescription claims in British Columbia to 
identify factors associated with the rising use of short-acting, beta2-agonists in the 
province (28).  Consistent with the recent trend of asthma prevalence reaching a plateau 
(7), researchers discovered that short-acting beta2-agonists prescription claims did not 
increase or decrease between 1996 to 1998. They also discovered that inhaled 
corticosteroids did not increase in use in a trend analysis during that same period.   
Additionally, Lynd et al. discovered that adults between the ages of 18 to 34 
years were 1.5 times more likely to increase their short-acting beta2-agonist use than 
those less than 18 years of age.  Males were more likely than females to increase their 
beta2-agonist use by 1.7 times.  Persons receiving social assistance were 2.3 times more 
likely to increase their use of beta2-agonists than those who were not.  Finally, a varied 
dose of inhaled corticosteroids between 1996 and 1998 also affected the increase in 
short-acting beta2-agonist used (28).   
In research by Diette et al., factors associated with the overuse of short-acting 
beta2-agonists and the under use of inhaled corticosteroids were analysed from a sample 
of employed 18 to 65 year olds with asthma who were enrolled in managed health care 
plans (25).  Their results showed that inhaled beta2-agonists were the most frequently 
 
 
14
used medication in 1993, with 94.4% of moderate or severe asthma patients using these 
drugs, followed by inhaled corticosteroids (with 66.6% using). 
The most common combination used by subjects in this study was inhaled beta2-
agonists with inhaled corticosteroids (17.4% of patients) in 1993 (25).  The second most 
popular combination of medications was beta2-agonists, inhaled corticosteroids, and 
theophyllines (7.6% of patients). 
Short-acting β2-agonists were used excessively by 15.8% of the moderate to 
severe asthma patients and 3.6% of the mild asthma patients in the Diette et al. study 
(25).  Of the moderate to severe asthma patients who were using beta2-agonists 
excessively, 10.7% were not using any form of corticosteroid (inhaled or oral 
corticosteroid), but 42.7% were using only an oral corticosteroid.   
The excessive use of short-acting beta2-agonists appeared to be associated with 
more severe asthma symptoms.  Those with moderate to severe asthma who used beta2-
agonists excessively were more likely to use inhaled corticosteroids, although in 
insufficient amounts. Excessive users of inhaled short-acting β2-agonists were also more 
likely to have a peak flow meter, have greater asthma knowledge, be more likely to use 
other asthma medications, be more likely to use heath care services, and have greater 
satisfaction with their care.  Excessive beta2-agonist use was also associated with being a 
patient of a pulmonologist rather than a general practitioner or allergist (25). 
Inhaled corticosteroids were underused by 64% of the moderate to severe asthma 
patients.  Inadequate use of inhaled corticosteroids was associated with using less beta2-
agonists, being female, being non-white, being younger (18-34 years old), having fewer 
asthma symptoms, and working full time (25).  It was also associated with not having a 
peak flow meter, lacking asthma knowledge, being less likely to use other asthma 
medications, being less likely to use hospital or emergency departments in the last year, 
and having lower satisfaction with care.  Under use of inhaled corticosteroids was also 
associated with being a patient of generalist rather than a pulmonologist or allergist. 
In a recent study by Blais et al. to assess the appropriate use of inhaled short-
acting β2-agonists and inhaled long-acting beta2-agonists in the province of Quebec, 
researchers found that short-acting beta2-agonists were overused, inhaled corticosteroids 
were underused, and long-acting beta2-agonists were used inappropriately (according to 
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the 1996 CCG) (29).  The subjects in the study were covered by the Régie de l’assurance 
maladie du Québec (RAMQ) which covers persons 65 years old and older, welfare 
recipients, and persons without access to group health insurance.  The highest proportion 
of appropriate use of short-acting beta2-agonists was among the youngest asthma 
patients in the study (5-18 years old).  Appropriate use of medications was greater when 
prescribed by a specialist, pediatricians (for short-acting beta2-agonists) and 
respirologists (for long-acting beta2-agonists). 
Researchers showed that while appropriate use was best among those aged 5-18 
years, the RAMQ drug plan in Quebec provides free prescription medications to children 
less than 18 years of age.  Blais et al. offered that since inhaled corticosteroids are much 
more expensive than short-acting beta2-agonists, differential costs may help to explain 
why appropriateness in use declines after the age of eighteen.  Adult male patients were 
of particular concern to researchers in the study because of their high inappropriate use 
of inhaled short-acting beta2-agonists (29).     
In an earlier study by Laurier et al. in the early 1990s in the province of Quebec 
(using a similar population to the previously mentioned Quebec study), researchers 
found that those who used theophyllines comprised the largest proportion of users 
(75.1% in the seniors group and 68.4% in the income security [welfare] recipients 
group) receiving ambulatory drug reimbursement programs (30).  Inhaled beta2-agonist 
users made up the second most populous group with 60.3% of seniors and 57.6% of 
welfare recipients.  Inhaled corticosteroid users made the third most populous group 
with 43.2% of seniors and 35.6% of welfare recipients. 
Upon sampling these two populations to discover which specific asthma drugs 
were being utilized, the results were similar for the two groups.  That is, both the seniors 
and the welfare recipients used beta2-agonist inhaled salbutamol 100 µg most commonly 
(46.1% for seniors and 40.4% for welfare recipients) and both had 4.1 mean 
prescriptions per year (30). Most of the subjects used at least one form of theophylline.  
Researchers found that the seniors’ mean number of prescriptions per year were slightly 
greater for all asthma drugs compared to the welfare recipients.  The most common 
combinations of preparations for both seniors and welfare recipients were inhaled beta2-
agonists and inhaled corticosteroids (43% for seniors and 34.9% for welfare recipients), 
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followed by short-acting inhaled beta2-agonists, inhaled corticosteroids, and 
theophyllines.  The third most commonly used combination was beta2-agonists, inhaled 
corticosteroids, theophyllines, and ipratropium bromide (30). 
 
 2.2.3.2  Asthma and seasonality 
 The literature concerning the relationship between the seasons and asthma 
focussed mainly on asthma hospitalizations and/or emergency room treatment as the 
outcome measure.  The research is certain and unanimous on one area, that adults and 
children must be separated in these studies as they are affected by the seasons differently 
and distinctly (31). The results across the reviewed research showed that pre-school and 
school age children experienced peak seasonal asthma exacerbations in September, and 
then had disease lows or seasonal troughs over the summer months, particularly in 
August (31-33).  They then had peak exacerbations in December, secondary to those in 
September.  In January there was a sudden drop in exacerbations that was inconsistent 
with researcher’s expectations, but was not explored (31-33).  
 In the Crighton et al. study, the most important finding was that seasonal patterns 
were driven by the youngest (0-4 years) group, in particular by males.  This influence 
was reversed in older groups where females were hospitalized more often.  A significant 
difference was found between males and females in the 0-4 year, and 5-9 year old age 
groups, wherein males were hospitalized two to three times the rate of females.  The 
older subjects in the study had little change for either sex.  The variation for adults that 
could be observed was for those aged 60 years and older (32).  
 In the Johnston et al. study, researchers established the association between the 
presence of rhinoviruses and asthma exacerbation, with some children needing to go to 
the emergency room (33).  Those who did not seek emergency care, the controls, turned 
out to have more severe asthma than the cases and had controller medication prescribed 
to them.  Controls used environmental control measures such as anti-dust mite bed 
sheets.  Researchers also investigated insurance claims for children’s prescriptions for 
inhaled corticosteroids.  They found claims were lowest in August which suggested that 
children may be using less controller medication immediately before the school year 
when they were at greatest risk for a virally induced asthma exacerbation.  Researchers 
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also suggested that children may be additionally exposed to a greater allergen load upon 
return to school in September.  Johnston et al. concluded that children using anti-
inflammatory medication were less likely to go to the emergency room during the period 
of expected peak exacerbations (33). 
 Seasonal variation in asthma among children was shown to be the same in 
England (from eight years of collected data) as it has been in other similar time-trend 
studies (31).  Children 0-4 years and 5-14 years old had asthma exacerbations, as 
measured by hospital admissions, peaked 100% above the average in late September, 
followed by a lesser peak in early December.  When measured by general practitioner 
visits, asthma exacerbations peaked 25% above average in early December followed by 
late September.  Both age groups had minimum values, below average, in August. 
 For adults in this English study, those aged 15-44 years had peak hospital 
admissions in late September, and peak general practitioner visits at 30% above average 
in late June and late September.  For adults of 45-64 years of age, hospital admissions 
were elevated during the winter while general practitioner visits were raised for a short 
period at the end of June (31). 
 
2.3  Summary and Conclusions 
The studies reviewed reveal the trend for a strong reliance on the reliever 
treatment arm of pharmacological asthma management.  Despite recommendations by 
asthma control experts, asthma patients using medication have continued to favour the 
use of bronchodilators (short-term inhaled rescue medications) over inhaled 
corticosteroids (long-term anti-inflammatory medications).  
The studies reviewed are based on aggregated data, limiting evaluation of 
individual drug use patterns associated with prevalence, diagnosis, severity of disease, 
morbidity and mortality.  Also, the studies do not include all age groups which limit 
knowledge of drug use patterns for the general population and comparability across 
studies.  
Several studies have used the health insurance database alone to investigate the 
trends in asthma prevalence (34;35).  Other studies have used the health insurance 
database in conjunction with prescription drug databases to validate asthma diagnoses 
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and examine trends in asthma prevalence and use of asthma-related drugs (2;36). 
Validation studies have shown that health insurance claims provide a reasonably 
accurate, reliable and valid representation of health care utilization in the province of 
Manitoba (37;38).  The health insurance claims database was used to develop indicators 
of health and to predict health outcomes (39;40).  In a Saskatchewan based study during 
the 1980s, over 70% of the asthma patients had at least one asthma related drug 
prescription in each year of the study period (2). 
The reviewed research indicates that there has been an increase in the prevalence 
of asthma and that prevalence differs by age group and sex.  In most studies examining 
medication use there has been an increase in the prevalent purchase of all asthma 
medications.  Bronchodilators have been favoured over inhaled corticosteroids over the 
past two decades, although there is some indication that a shift in prescription and drug 
purchase toward more anti-inflammatory medications may be occurring.  This behaviour 
shift, if real, supports the CCG for the management of asthma.   
Continued research and surveillance at the individual level of data analysis is 
warranted.  This information is invaluable for the evaluation of treatment guidelines and 
practice.  It also enhances general understanding of the epidemiology of the disease.  
Ongoing study of the use patterns of inhaled corticosteroids alone and in combination 
with bronchodilators in populations of children and adults with moderate to severe 
asthma would be an important contribution to our understanding of the disease. 
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3.  RESEARCH METHODS AND PROCEDURES 
 
3.1  Introduction 
This thesis work is one part of a larger study being conducted by Dr. A. 
Senthilselvan and Dr. J.A. Dosman entitled Prevalence, Severity and Treatment of 
Asthma in Saskatchewan, 1989 to 1998. The overall objectives of that study are as 
follows: 
 
1. [determine] changes and regional variations in period prevalence of 
physician-diagnosed asthma, chronic obstructive pulmonary disease 
(COPD), and bronchitis; 
 
2. [determine] changes and regional variations in severity of asthma, 
COPD, and bronchitis; 
 
3. [determine] period prevalence and severity of asthma, COPD, and 
bronchitis among the registered Indian population; 
 
4. [determine] changes and regional variations in use of asthma 
medication among asthma cases. 
 
The purpose of the analysis herein, is to address the fourth objective of the larger 
study.  The larger study received compiled data from The Saskatchewan Health 
Department to address its research questions.  The databases used to compile data for 
this portion of the research were a demographic information database, The Physician 
Services Database and the Outpatient Prescription Drug Database.   
Information regarding hospital services from the Hospital Services Database was 
supplied to the primary researchers of the larger study.  This information was not 
necessary to the research questions concerning this particular study. 
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3.2  International Classification of Disease for Asthma 
The International Classification of Diseases (ICD) is an internationally 
recognized structured coding system published by the World Health 
Organization and it was used to classify asthma cases in the overall study.   
 All individuals covered under the provincial health plan that received a 
coding of 493.0 by a physician for each year of the study, from January 1, 
1991 to December 31, 2000, were included in the asthma database.  Code 
493.0 is extrinsic asthma (asthma without mention of status asthmaticus). 
  
3.3  Data Source 
The Outpatient Prescription Drug Database and The Physician Services 
Database, which were combined for this study’s purposes, were originally established 
for administrative purposes. Their primary function is to record and process services 
rendered by the health care system so that health care professionals and organizations 
can be appropriately remunerated. The Physician Services Database consists of a record 
of persons who have visited their physician at least once in a given calendar year, from 
January 1, 1991 to December 31, 2000, and received a diagnosis of asthma. The purpose 
of the visit is recorded according to a fee for service billing schedule by the physician 
and submitted to Saskatchewan Health.  
Saskatchewan Health uses the Person Registry System (PRS) which is a central 
computer file that contains the unique health services number (HSN), name, address, 
sex, date of birth, and dates of health coverage initiation and termination of every 
individual under Saskatchewan Health’s jurisdiction. This file is updated daily for name 
or address changes, births, deaths, and new arrivals and departures from the province 
(41). Saskatchewan residents are required to obtain a health card to receive health care 
benefits from the provincial government. The nine-digit HSN on the health card 
uniquely identifies each eligible client. The HSN and attached information are 
maintained in the Health Insurance Registration File (HIRF) and are updated regularly 
by the Health Registration Department. 
The Physician Drug Database containing information pertaining to an 
individual’s physician visit is combined with their demographic information as a 
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healthcare client including: a pseudo-identification number (replacing the HSN); age (in 
5-year age categories from 0 to 64 years); sex; health district; service date, and; primary 
diagnosis.  
The Outpatient Prescription Drug Database is a record of Saskatchewan residents 
who have filled at least one drug prescription in any given year from January 1, 1991 to 
December 31, 2000. The database provides information regarding the name, dispensing 
date, drug class and drug category, quantity, strength, and form of any medication 
purchased by an individual in Saskatchewan covered under the provincial health 
insurance plan under the control of the Medical Services Branch of Saskatchewan.  For 
the purposes of this study, a pseudo-identification number linked these individuals 
across all databases under the management of Saskatchewan Health.  
 
3.4  Study Design 
This is a descriptive study based on data drawn from the population of all 
Saskatchewan residents covered under the provincial health insurance plan from January 
1, 1991 to December 31, 2000.  There is a high level of detailed patient/client 
information in these databases, which a can be relied upon for a reasonable degree of 
accuracy. Both this and the larger study are ensured a suitable level of confidence in the 
identification of nearly all known cases of asthma and the purchase of asthma 
medications in the Province of Saskatchewan from 1991 to 2000. 
  
3.5  Subjects for Analysis 
Health insurance coverage is extended to all residents of the Province of 
Saskatchewan by the provincial government with the exception of members of the 
Canadian Armed Forces, members of the Royal Canadian Mounted Police and, inmates 
of federal prisons (42). These groups are insured under federal government programs. 
Those persons identified as Metis or First Nations are also often covered under federal 
health care plans. First Nations persons who were covered under the provincial health 
care insurance plan for the study period were identified by Saskatchewan Health using 
the Person Registry System (PRS) and excluded from these analyses.  All other 
Saskatchewan residents who were covered under the provincial health care insurance 
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plan from January 1, 1991 to December 31, 2000 formed the study population from 
which subjects were drawn.  Figure 3-1 describes the conceptual framework used for 
asthma subject extraction. 
The Outpatient Physician Services database contains information sent by 
physicians for payment for medical services rendered to patients (fee for service or 
alternate payment plan). The Outpatient Prescription Drug database includes information 
of all prescription drugs purchased by Saskatchewan clients. These drugs are listed in 
the Saskatchewan Formulary which is updated yearly (43).  
For each calendar year from January 1, 1991 to December 31, 2000, the study 
utilized data complied by Saskatchewan Health that electronically linked persons with 
extrinsic asthma (ICD9: 493.0) between databases.  Persons with asthma identified in 
each calendar year in the Outpatient Physician Services database were joined to their 
individual purchases of asthma medications in the Outpatient Prescription Drug 
database.  
To maintain confidentiality, 5-digit residence codes were provided only for those 
subjects living in cities with a population of 10,000 or more. For subjects living in 
smaller centres (<10,000), identification of those living in townships and rural areas was 
gathered and provided by Saskatchewan Health with the original data set.   
For each year, Saskatchewan Health linked physician-diagnosed asthma cases (ICD9: 
493.0) to the individual’s use of the Outpatient Prescription Drug database. In 
addressing the analysis of the proportion of the medication purchases within the first 
thesis question, all Saskatchewan residents with physician-diagnosed asthma, who were 
covered under the provincial healthcare insurance plan between 1991 and 2000, were 
included in the denominator.  For the remaining thesis questions, only persons who 
appeared in the Outpatient Prescription Drug database each year were included in the 
analyses. 
 
3.5.1  Age categories 
The division of age categories was based on the study of the prevalence of 
asthma in Saskatchewan for the years 1981 to 1990 (2) which served as a parent 
document for this study. 
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Figure 3-1  Data extraction and analysis conceptual framework. 
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3.6  Operational Definitions 
Asthma:  A subject was defined as having asthma by the first visit to a physician in each 
calendar year, at which time the subject received a diagnosis of ICD9: 493.0. 
Purchaser: The terms user and purchaser are used interchangeably. 
Use (of medications): The term “use” describes the purchase of one or more asthma 
prescription medications by persons with physician-diagnosed asthma. 
User: A user is defined as a person with physician-diagnosed asthma in each study year 
that has purchased at least one prescription of asthma medication. 
 
3.7  Ethical Considerations 
The anonymity of the subjects in this study was assured by Saskatchewan Health 
through the replacement of their Health Service Numbers (HSNs) with pseudo-
identification numbers. The database consisted of large numbers of cases, an average of 
29,643 persons per year for the ten years of the study period.  
As indicated on the ethics approval found in Appendix A, the asthma database is 
accessible only to those persons involved in the larger study, Prevalence, Severity, and 
Treatment of Asthma in Saskatchewan, 1989 to 1998, under the supervision of Dr. A. 
Senthilselvan and Dr. D. Rennie.  Upon conclusion of the study herein, access to the 
database will be discontinued, and all working copies of the database will be erased or 
given to Dr. A. Senthilselvan.  
 
3.8  Data Analysis 
Variables were examined by using frequencies and cross tabulations. The linear 
by linear test for trends was used for examining categorical data over time.  Differences 
were claimed to be statistically significant when the p value was less than 0.05. 
Statistical computations were performed using SPSS version 11.0 software. 
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3.8.1  Research question 1: 
For each calendar year, the proportion of asthma cases that purchased asthma 
medication was obtained for age, sex, region, and medication group. There was a change 
in the health region boundaries in Saskatchewan in 1993 from 33 Health Districts to 13 
Regional Health Authorities.  The current northernmost health region consisted of three 
Health Authorities: Athabasca; Keewatin Yatthé; and, Mamawetan Churchill River.  For 
this study, regional health authorities were used to examine proportions of asthma users 
by region.  Changes in the proportion of asthma medication use over time were 
examined using a linear by linear test for trends analysis. The denominator for this 
portion of the analysis was all physician-diagnosed cases of asthma that had at least one 
physician visit for each calendar year.   
For each calendar year, the mean (standard deviation, sd) number of asthma 
medications per person was examined by age, sex, and medication group for all asthma 
cases that purchased at least one asthma medication.  The denominator for these 
analyses included only those cases where a purchase of at least one asthma medication 
occurred in a given calendar year. Changes in the mean (sd) number of asthma 
medications over time were examined by age group, sex, and by sex within age groups.  
The overall mean number of prescriptions and the proportion of purchasers by drug 
group for the ten year study period were examined.  The mean number of prescriptions 
per purchaser was examined by sex within age groups for 1991, 1994, 1997, and 2000.  
Finally, for the year 2000, each medication group was assessed for associations with sex, 
and sex within age group using chi-square test for proportion.    
 
3.8.2  Research question 2:  
The concurrent use of asthma medications was investigated by obtaining the 
proportions of combinations of prescriptions purchased by asthma cases in each calendar 
year.  Persons who used only short-acting, beta2-agonists or only inhaled corticosteroids 
were included in these analyses.  Persons who used single preparations of oral 
corticosteroids, antispasmodics, respiratory smooth muscle relaxants, or unclassified 
therapeutic agents were excluded.  The proportion of persons using specific asthma 
medication combinations was examined over the ten years.  The years 1991, 1994, 1997, 
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and 2000 were highlighted for examination of combination use by age groups.  Changes 
in the proportion of asthma medication use over time were examined using the linear by 
linear test for trends. The denominator for this portion of analysis was physician-
diagnosed cases of asthma that utilized the Outpatient Prescription Drug Plan for the 
purchase of asthma medications for each given year, excluding those who used only 
single preparations of medications of the above excluded (single use) drug groups in 
each calendar year. 
 
3.8.3  Research question 3: 
For each calendar year, for the years 1996 to 2000, the numbers of inhaled short-
acting β2-adrenergic agonist and inhaled corticosteroid prescriptions used per month 
were calculated.  The frequencies of monthly prescriptions were examined by age 
groups, and sex for these years.   Trends in the number of prescriptions were tested using 
linear by linear test for trends.  The denominator for this portion of analysis was all 
physician-diagnosed cases of asthma who utilized the Outpatient Prescription Drug Plan 
for the purchase of asthma medications at least once in a given calendar year. 
 
 
 
 
 
 
 
 
 
27
 
 
 
 
4.  RESULTS 
 
4.1  Research Question #1:  
Is there variation in percentage of users of each drug for the treatment of asthma 
by age, gender and region per year and in the mean number of asthma medications 
per person by age, gender per year from January 1, 1991 to December 31, 2000? 
 
4.1.1  Users with asthma by year 
Table 4-1 shows the proportion of persons in the asthma population of 
Saskatchewan for the years 1991 to 2000 who purchased at least one asthma medication 
in each year.  The average number of persons with asthma, between the ages of 0 to 64, 
in the years 1991 to 2000 was 29,643 persons.  The year with the lowest population of 
persons with asthma was 1991 with 25,277 persons.  The highest asthma population year 
was in 2000, with 32,621 persons. 
 
Table 4-1  Total number of persons with asthma in Saskatchewan aged 0 to 64 and 
proportion who purchased at least one asthma medication by year, 1991 to 2000* 
Year 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Total 
Total population (N) 25277 26058 27562 28825 30234 31048 31461 31071 32273 32621 296430 
% purchased one or 
more prescription 76.1 76.1 74.8 76.1 78.4 78.4 77.7 77.6 79.3 78.8 77.4 
*persons received a diagnosis of asthma with their first physician visit for each year 
 
On average, 77.4% of persons between the ages of 0 to 64 years used at least one 
asthma drug.  There was a small increase in the proportion of persons with asthma who 
purchased asthma medication over the 10 year study period, which was a significant 
result on a linear by linear test for trend at: χ2 = 214.5, df 1, p < 0.001.  The year in 
which the lowest proportion of the asthma population in Saskatchewan purchased at 
least one asthma medication was 1993.  The greatest proportion of purchasers was in 
1999 with 79.3% of the asthma population purchasing at least one asthma medication.  
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4.1.2  Users with asthma by age and year 
For 1991 to 2000, those aged 35 to 64 years were the greatest purchasers of 
asthma medications (78.2%), followed by 15-34 year old purchasers (77.3%) (Table 4-
2).  The average proportion of 5-14 year old medication purchasers with asthma was 
77.2% and the average proportion of 0-4 year olds was 75.4% over the ten year period of 
the study. 
Children aged 0-4 years had the highest increase in the proportion of users of 
asthma medication between 1991 and 2000 (6.1%).  Users in all age groups decreased in 
the percentage of persons purchasing asthma medications in 1993. The decrease was 
small for the 15-34 year old age group in comparison to other age groups.  In the last 
two years of the study period, all of the age groups had similar proportions of asthma 
medication users, which was slightly less than 80% of the asthma population.  The linear 
by linear test for trends within each age group had significant results (all p < 0.001). 
 
 
 
Table 4-2  Number of persons with asthma and proportion who purchased an asthma 
medication by age and year, 1991 to 2000.*  
 0-4 years 5-14 years 15-34 years  35-64 years 
Year % N† % N† % N† % N† 
1991 73.9 3971 77.5 7870 75.5 7013 76.4 6423 
1992 73.9 4084 76.1 7836 76.6 7413 76.6 6725 
1993 72.1 3973 73.8 8440 76.1 8093 75.8 7056 
1994 73.5 3933 75.8 8902 76.8 8574 77.0 7416 
1995 75.2 4105 78.6 9460 78.4 8829 79.8 7840 
1996 74.7 4228 77.8 9276 79.0 9207 80.2 8337 
1997 76.0 4156 76.8 8972 77.8 9344 79.3 8989 
1998 75.4 4113 76.6 8336 77.9 9516 79.0 9106 
1999 78.8 4122 79.5 8820 77.8 9571 80.6 9760 
2000 80.0 3973 79.3 8466 77.5 9978 79.0 10204 
Total 
average 75.4 4066 77.2 8638 77.3 8754 78.2 8186 
*NB: persons received a diagnosis of asthma with their first physician visit for each year 
†N is the denominator  
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4.1.3  Users with asthma by sex and year 
As observed in Table 4-3 during the ten year study period, there was a greater 
average proportion of males who purchased at least one asthma medication compared 
with females (78.1% versus 76.5%).  The difference between sexes was approximately 
2.0% for most years and was found to be significant (p < 0.001).  The difference 
between males and females appeared to decrease by 2000. As the male proportion of 
medication purchasers increased moderately, from 77.5% to 79.4% over the ten year 
period, the female proportion of purchasers increased (from 74.4% to 78.1%).  As seen 
previously, in the year 1993 there were fewer purchasers of asthma medication for both 
sexes. 
 
 
Table 4-3  Number of persons with asthma and proportion of users, aged 0 to 64, in 
Saskatchewan by sex and year, 1991 to 2000  
 
 
 
 
 
 
 
Year Male Female 
   % N % N 
1991 77.5 13509 74.4 11768 
1992 77.0 13776 75.0 12282 
1993 75.7 14506 73.7 13056 
1994 76.8 15017 75.3 13808 
1995 78.9 15963 77.9 14271 
1996 79.1 16063 77.5 14985 
1997 78.0 16212 77.4 15249 
1998 77.9 15999 77.2 15072 
1999 80.2 16444 78.3 15829 
2000 79.4 16733 78.1 15888 
Overall 78.1 15422 76.5 14221 
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4.1.4  Users by health region and year 
As Table 4-4 shows, a similar proportion of the population purchased at least one 
asthma medication within a given year of the study period in all health regions, with the 
exception of the Northern health region.  In contrast to the increases observed in other 
health regions over the ten year study period, the proportion of users in the Northern 
health region decreased over time and had almost 11.0% fewer purchasers per region 
than all other 10 health regions from 1994 onward. 
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4.1.5  Distributions of asthma prescriptions by age group and calendar year 
The number of asthma prescriptions purchased over the ten year study period 
increased from 129,763 in 1991 to 139,486 in 2000 (Table 4-5). The smallest number of 
asthma prescriptions was purchased in 1993 (113,997).   
The percentage of the total asthma prescriptions per year increased with 
successive age groups. The 0-4 and 5-14 year old age groups had the lowest percents of 
asthma prescriptions in each year of the study.  
 
 
Table 4-5 Percentage of asthma prescriptions purchased by persons with asthma in 
Saskatchewan by age and year, 1991 to 2000* 
Year Total 0-4 years 5-14 years 15-34 years 35-64 years 
 N % N % N % N % N 
1991 129763 10.4 13441 24.3 31554 27.4 35517 38.0 49251
1992 126549 10.6 13436 22.8 28829 28.4 35937 38.2 48347
1993 113997 9.6 10934 21.7 24734 30.0 34150 38.8 44179
1994 119297 9.4 11217 22.3 26620 30.2 36074 38.0 45386
1995 130544 9.6 12574 22.8 29758 29.1 37942 38.5 50270
1996 133388 9.7 12932 21.0 28026 29.6 39485 39.7 52945
1997 131813 9.5 12474 19.4 25602 29.1 38321 42.0 55416
1998 129115 8.9 11440 18.2 23497 29.6 38206 43.4 55972
1999 138975 9.7 13445 19.6 27193 27.6 38302 43.2 60035
2000 139486 9.3 13041 19.0 26481 28.4 39672 43.2 60292
10 year 
average 129293 9.7 12493 21.1 27229 29.0 37361 40.3 56627
*Persons received a diagnosis of asthma with their first physician visit for each year 
 
The 35-64 year old group was the only group to increase in the percentage of 
asthma prescriptions over the study period. The 35-64 year old group had the highest 
percentage of prescriptions in every calendar year and at least 7.0% higher than all other 
age groups throughout the study period. 
 
 
 
33
4.1.6  Distribution of asthma prescriptions by sex and calendar year 
The percentage of prescriptions was consistently greater for males over the ten 
year period than it was for females (Table 4-6). The proportion of prescriptions for 
males decreased over the study period while that of females increased.  The sex 
difference was narrowed toward the year 2000.  
 
Table 4-6  Percentage of asthma medication purchased by persons with asthma, aged 0 
to 64, in Saskatchewan by sex and year, 1991 to 2000* 
Year Total Prescriptions Male Female 
 N % N % N 
1991 129763 56.1 72781 43.9 56982 
1992 126549 55.1 69717 44.9 56832 
1993 113997 54.4 62043 45.6 51954 
1994 119297 54.0 64478 46.0 54819 
1995 130544 53.9 70353 46.1 60191 
1996 133388 52.9 70563 47.1 62825 
1997 131813 51.8 68295 48.2 63518 
1998 129115 52.5 67765 47.5 61350 
1999 138975 52.0 72258 48.0 66717 
2000 139486 51.8 72289 48.2 67197 
Total 
mean 129293 53.5 68874 46.6 60239 
 *Persons with asthma purchased at least one asthma medication in each year 
 
4.1.7  Mean number of prescription purchases by year 
Overall, mean prescription purchases decreased over the ten years of the study 
(Table 4-7).  For each year, from 1991 to 2000, the standard deviation for the mean 
number of prescription purchases per year was greater than the mean number itself.  This 
indicated large variability in the data. 
 
4.1.8  Mean number of prescription purchases by age group and year 
For all age groups, the mean number of prescription purchases decreased from 
1991 to 2000 (Table 4-8).  Those aged 0-4 years and 5-14 years had the lowest mean 
prescription purchases.  The 35-64 year old group had the highest mean prescription 
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purchases.  The 0-4 year old group had the least change in mean purchases over the ten 
year study period.  The 35-64 year old group had the greatest decrease in the mean 
number of prescriptions from 1991 to 2000 (2.6%). 
 
4.1.9  Mean number of prescription purchases by sex and year 
 When mean prescription purchases were examined by sex for the years 1991 to 
2000, there were decreases for both males and females (Table 4-9).  For all years of the 
study period, males had more average prescription purchases per year than females.  
When the mean number of prescription purchases was considered by age and sex (Table 
4-10), the greatest differences were found for the 15-34 year old and 35-64 year old 
groups.  Within each age group from 1991 to 2000, males had a larger mean number of 
prescriptions than females.  By 2000, both males and females in the 35-64 year old 
group had the highest mean number of prescription use, 7.81 and 7.23, respectively. 
Tables 4-8 and 4-9 showed that the mean number of prescriptions decreased 
sharply for both sexes, within and across age groups, from 1991 to 1993 and seemed to 
plateau or stabilize to 2000.  
 
Table 4-9  Mean number of prescriptions purchased by persons with asthma by sex and 
year, 1991 to 2000 
Year Male Female All 
 Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. 
1991 7.0 8.44 6.5 8.07 6.8 8.27 
1992 6.6 7.79 6.2 7.75 6.4 7.78 
1993 5.7 6.55 5.4 6.74 5.5 6.64 
1994 5.6 6.55 5.3 6.52 5.4 6.54 
1995 5.6 6.44 5.4 6.62 5.5 6.52 
1996 5.6 6.51 5.4 6.85 5.5 6.68 
1997 5.4 6.44 5.4 6.79 5.4 6.61 
1998 5.4 6.34 5.3 6.74 5.4 6.54 
1999 5.5 6.29 5.4 6.88 5.4 6.56 
2000 5.4 6.12 5.4 6.80 5.4 6.46 
Overall 5.7 6.75 5.5 6.96 5.6 6.85 
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4.1.10  Proportion of users and mean number of prescriptions by drug groups 
The drug groups selected for this portion of the analysis were the major 
medications used by persons with asthma over the ten year study period.  Separated into 
medication groups according to the Saskatchewan Health Prescription Drug Plan 
Formulary (43), we observed which asthma medications increased and decreased over 
the ten years of the study period (Table 4-11). 
   
 4.1.10.1  Short-acting inhaled beta2-agonists 
Short-acting, inhaled beta2–agonists were the predominant asthma medication 
used by persons with asthma in this study. This was reflected both in the proportion of 
persons purchasing the medication and within their mean number of prescriptions.  Over 
the study period the proportion of persons purchasing inhaled short-acting beta2–
agonists remained relatively steady, but the mean number of prescriptions gradually 
decreased. 
Between 1991 and 1993 there was a significant decline in the purchasing of 
inhaled beta2-agonists, from 79.7% in 1991 to 75.9% in 1993. After 1993, the proportion 
purchased increased gradually to the end of the study period to maintain a percentage in 
the upper seventies.  
 
 4.1.10.2  Inhaled corticosteroids 
The greatest increase in use over the ten year study period was in the inhaled 
corticosteroid medication group, from 41.5% in 1991 to 70.4% in 2000. Mean 
prescription drug purchases nearly doubled by 2000 but were still much lower than the 
mean number of prescriptions of inhaled short-acting beta2-agonists.  
 
 4.1.10.3  Oral corticosteroids 
The proportion of persons purchasing oral corticosteroids increased over the ten 
year study period.  However, the mean number of prescriptions per person remained 
relatively constant throughout the study period. 
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 4.1.10.4  Oral beta2-agonists 
  In 1991, 16.2 percent of the population of persons with asthma was taking oral 
beta2-adrenergic agonists. Over the ten years of the study period that number decreased 
steadily to 4.3 percent in 2000.  
 
 4.1.10.5  Theophyllines 
In the early years of the study there was a sizable proportion of persons 
purchasing theophyllines (15.1%) and a notable mean number of theophylline 
prescriptions purchased per user (0.60%).  Both of these measures decreased markedly 
by the year 2000. 
  
 4.1.10.6  Sodium cromoglycates 
 At 25.4% in 1991, sodium cromoglycates were purchased by a large percent of 
persons with asthma.  This percentage decreased rapidly over the ten years of the study 
ending with 1.0% prescriptions purchased per year in 2000. The mean number of 
prescriptions also decreased quickly from 0.79 in 1991 to 0.03 in 2000.  By the end of 
the study, sodium cromoglycates seemed to disappear from use by persons with asthma. 
 
4.1.10.7  Inhaled ipratropium bromide 
Relative to some of the other asthma medications used during the study period, 
the proportion of purchasers and mean number of prescriptions for inhaled ipratropium 
bromide was low.  However, from 1991 to 2000 the proportion of persons purchasing 
inhaled ipratropium bromide doubled, as did the mean number of prescriptions.  
Although the mean prescriptions for inhaled ipratropium bromide decreased from 0.12 
in 1991 to 0.09 in 1993, the mean number of prescriptions increased from 1993 to the 
end of the study period.  
  
 4.1.10.8  Long-acting beta2-agonists 
Long-acting beta2-agonists were not purchased by persons in the asthma 
population until 1995.  By 2000 the proportion of purchasers was 1.7%. 
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 4.1.10.9  Nedocromil and ketotifen 
Nedocromil and Ketotifen were used by a small percentage of the population, at 
most 2.0% of users, and in very small quantities, at most 0.06 mean prescriptions. Both 
medication groups showed a decline in use during the study period. 
 
 4.1.10.10  Combination medication (salmeterol and fluticasone) 
The combination drug of the long-acting beta2-agonist, Salmeterol, and the 
inhaled corticosteroid, Fluticasone, was not purchased by persons with asthma until the 
year 2000.  
 
 4.1.10.11 Anti-leukotrienes 
As a new class of medication, the anti-leukotrienes provided only two years of 
data. In 1999 the percent of anti-leukotrienes purchased by persons with asthma was 
1.8%, and the mean was 0.08 prescriptions per year. In 2000, the proportion of 
purchasers was 3.1% and the mean number of prescriptions had increased to 0.18.  
 
4.1.11  Mean number of prescriptions for 1991, 1994, 1997, and 2000 
Four years of data (1991, 1994, 1997, and 2000) were examined to compare the 
prescription purchasing behaviour of persons with asthma by class of asthma 
medication.  Each year was compared to the next in chronological order and an overall 
comment was made after all four years were reviewed individually. 
 
 4.1.11.1  Mean number of prescriptions for 1991  
Inhaled short-acting beta2-agonists had the greatest mean number of prescriptions 
compared to all other drugs for the treatment of asthma in 1991 (Table 4-12). This mean 
increased with successive age groups, with the 35-64 year old age group having the 
greatest mean number of prescriptions. In all of the age groups, males had a greater 
mean than females.  The difference in the mean number of prescriptions between males 
and females increased within increasing successive age groups. 
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With inhaled corticosteroids in 1991, the mean number of prescriptions increased 
with successive age groups, from 0.35 for 0-4 year olds, to 2.12 for the 35-64 year olds. 
There appeared to be little difference between the 5-14 year olds, at 0.91 mean 
prescriptions per year, and the 15-34 year olds at 1.00 mean prescriptions. The 
difference between males and females was small for all age groups, except the 35-64 
year old group, which had a difference of 0.32. 
Oral corticosteroids had the greatest mean number of prescriptions among the 
35-64 year old group, 0.69 mean prescriptions per year, though again, the mean 
prescriptions increased with age groups.  The smallest mean number of prescriptions 
was among the 5-14 year old group with 0.12 mean prescriptions per year, followed by 
the 0-4 year old group with 0.14 mean prescriptions per year. The difference between 
males and females was small for all age groups. 
In 1991, oral beta2-agonists were utilized most by younger children.  The 0-4 
year old age group had the highest mean number of prescriptions, at 0.78, followed by 5-
14 year olds at 0.29. The difference between males and females was small for all age 
groups. 
In 1991, the mean number of prescriptions for theophyllines per year increased 
with age from 0.18 for 0-4 year olds to 1.50 for 35-64 year olds. The difference between 
males and females was small for all age groups except for the 35-64 year old group, 
which had a difference of 0.21. 
Sodium cromoglycates seemed to be used for children, since the mean number of 
prescriptions per year decreased with decreasing age groups for the year. Those aged 0-4 
had the greatest mean at 1.47 prescriptions per year in 1991, and those aged 5-14 had 
1.11 mean prescriptions per year. The two older age groups (15-34 years and 35-64 
years old) had much smaller means, and the difference between males and females was 
smaller within the older age groups. In the two younger age groups, males had much 
higher mean prescriptions of sodium cromoglycates than females. 
Inhaled ipratropium bromide seemed to be a drug purchased mainly by the 35-64 
year old age group with a mean number of 0.31 prescriptions per year.  Other age 
group’s means were 0.50, for 5-14 year and 15-34 year olds, and 0.70 for 0-4 year olds. 
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The difference between males and females was small for all age groups except for the 
35-64 year old group, which had a difference of 0.10. 
 
 4.1.11.2  Mean number of prescriptions for 1994 
In 1994, short-acting inhaled beta2-agonists had the greatest mean number of 
prescriptions compared to all other drugs for the treatment of asthma, except for the 0-4 
year old age group for whom inhaled corticosteroids were highest (Table 4-13). As in 
1991, the mean number of inhaled beta2-agonist prescriptions increased with increasing 
age. For all age groups, males had a greater mean than females.  The sex difference was 
much greater within the two older age groups (15-34 years and 35-64 years old) than 
within the two younger age groups. From 1991 to 1994, the mean number of inhaled 
beta2-agonist prescriptions decreased for all groups. 
From 1991 to 1994, the mean number of inhaled corticosteroid prescriptions 
increased for all groups. The 35-64 year old group still had the largest mean number, 
with 2.09 prescriptions per year, while the 0-4 year old group had the smallest, with 1.25 
inhaled corticosteroid prescriptions per year. In all age groups but the 0-4 year olds, 
males had moderately greater mean prescriptions than females. 
Oral corticosteroids had the same pattern in 1994 as in 1991. The mean number 
of prescriptions increased slightly, from 1991 to 1994, for all but the 35-64 year old 
group, which remained the same. The difference between males and females was small 
within all age groups. 
Oral beta2-agonists had greater mean numbers of prescriptions in the younger 
two age groups (0-4 year and 5-14 year olds) than the older groups, this was the same 
pattern found in 1991. The difference between males and females was small for all age 
groups. From 1991 to 1994, the mean number of oral beta2-agonist prescriptions 
decreased for all groups.  Mean theophylline prescriptions were low in all age groups 
except the 35-64 year old group in 1994.  From 1991 to 1994, the mean number of 
theophylline prescriptions decreased in all groups, especially in the two younger age 
groups (0-4 year and 5-14 year olds). The difference between males and females was 
small within all age groups except the 35-64 year old group, which had a difference of 
0.10. 
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Though the mean number of prescriptions per year was lower in 1994 than 1991 
for sodium cromoglycates, the pattern was the same. The two younger age groups (0-4 
year and 5-14 year olds), had greater mean prescriptions and greater differences between 
the means of males and females than the two older age groups (15-34 year and 35 to 64 
year olds).  
The mean number of prescriptions of inhaled ipratropium bromide per year for 
35-64 year olds was the same in 1991 and 1994. Mean prescriptions were low in all age 
groups except the 35-64 year old group. The difference between males and females was 
small for all age groups. 
In 1994 the mean numbers of prescriptions per year for Nedocromil and 
Ketotifen were very low. The means seemed to increase with successive age groups and 
the difference between males and females was small for all age groups.  
 
 4.1.11.3  Mean number of prescriptions for 1997 
In some user groups in 1997, short-acting inhaled beta2-agonists no longer had 
the greatest mean number of prescriptions compared to all other drugs for the treatment 
of asthma (Table 4-14).  Since the early 1990s, the mean number of short-acting inhaled 
beta2-agonists decreased while that of the inhaled corticosteroids increased. As in 
previous years, the mean number of short-acting beta2-agonist prescriptions increased 
with increasing successive age groups. Males were more frequent users than females and 
the difference between the means for sex appeared to be much greater within the older 
two age groups (15-34 year and 35-64 year olds) than within younger two age groups (0-
4 year and 5-14 year olds). From 1994 to 1997, the mean number of inhaled short-acting 
beta2-agonist prescriptions decreased for all groups.  
In 1997, inhaled corticosteroids had the highest mean number of prescriptions in 
the 0-4 year old and 5-14 year old age groups.  The same distribution of the mean 
number of inhaled corticosteroids prescriptions over age and sex in 1994, was found in 
1997 but the values were greater in 1997. The mean prescriptions increased most for the 
0-4 year old group from 1994 to 1997 (1.25 to 1.71). The difference between males and 
females was small for all age groups except the 5-14 year old group, which had a mean 
difference of 0.20 mean prescriptions per year.
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The mean number of oral corticosteroid prescriptions appeared mainly 
unchanged from 1994 to 1997 for all the age groups except for the 35-64 year old group, 
which decreased from 0.69 to 0.58 mean prescriptions. The same basic pattern existed 
for oral corticosteroids between 1994 and 1997.  Males had higher mean prescriptions 
than females in the 0-4 year old group and females had higher mean prescriptions in the 
15-34 year old group.  
For oral beta2-agonists the same distribution of mean prescriptions over age and 
sex found in 1994, was found in 1997 but the mean numbers were lower in 1997. The 
difference between males and females was small to nil for all age groups. 
The theophyllines group appeared to have the same pattern of mean prescriptions 
purchased in 1997 as was found in 1994 and 1991. The mean numbers of prescriptions 
themselves were lower than in previous years. There was little difference between males 
and females in all age groups. 
Compared to 1994, the mean number of prescriptions per year was lower in 1997 
for sodium cromoglycates across all age groups, for both sexes. As in 1994, in 1997, the 
two younger age groups had greater mean prescriptions than the 15-34 year old, and 35-
64 year old age groups.  
In 1997, the inhaled ipratropium bromide drug group increased the mean number 
of prescriptions in all age groups from 1994, most notably for the 35-64 year old group. 
The 35-64 year old group increased from 0.31 to 0.57 mean number of prescriptions 
purchased from 1994 to 1997. Inhaled ipratropium bromide’s mean prescription 
purchases were very low for those under 35 years of age. The difference between males 
and females was small to nil for all age groups. 
 
 4.1.11.4  Mean number of prescriptions for 2000 
In 2000, inhaled short-acting beta2-agonists had a high mean number of 
prescriptions compared to all other drugs for the treatment of asthma (Table 4-15). 
Short-acting inhaled beta2-agonists had the highest mean number of prescriptions in the 
15-34 year old, and 35-64 year old groups.  As observed in the previous three examined 
years, the mean number of prescriptions increased with successive increasing age 
groups. In all age groups, males had greater means than females and the differences 
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between the means were greater within the older two age groups (15-34 years and 35-64 
years old) than within the two younger age groups (0-4 years and 5-14 years old). 
From 1997 to 2000, the mean number of inhaled short-acting beta2-agonist 
prescriptions decreased for the two older age groups while the two younger age groups 
changed very little. The mean number of prescriptions decreased most for the 35-64 year 
old group from 1997 to 2000 (3.44 to 3.11). The 0-4 year old group increased, from 
1997 at 1.25 to 2000 at 1.26 mean prescriptions per year. 
Inhaled corticosteroids had the same distribution of mean number of 
prescriptions over age and sex in 2000 as was found in 1997, but the mean number of 
prescriptions had increased in 2000. The mean number of prescriptions increased most 
for the 0-4 year old group from 1997 to 2000 (1.71 to 2.16). The 15-34 year old group 
increased the least, from 1997 at 1.40 to 2000 at 1.42 mean prescriptions per year. The 
difference between males and females was small (for the two older age groups), to 
moderate (for the two younger age groups). 
The mean number of oral corticosteroid prescriptions appeared unchanged from 
1997 to 2000 for the 5-14 year old and 15-34 year old groups. From 1997 to 2000 the 
mean number of prescriptions decreased moderately for the 35-64 year old group while 
they increased moderately for the 0-4 year old group. There was a modest difference 
between males and females in all age groups, except within the 5-14 year old group.  
Oral beta2-agonists had the same distribution of mean number of prescriptions 
over age and sex in 2000 as was found in 1997.  The mean numbers of prescriptions 
were lower in 2000 than in 1997. The differences between males and females were small 
within all age groups.  The mean number of theophylline prescriptions decreased very 
little for all age groups except for the 35-64 year old group from 1997 to 2000, which 
decreased notably from 0.47 to 0.26. There was very little to no difference between 
males and females for all age groups in 2000. 
In 2000, the sodium cromoglycate drug group had all but disappeared from 
asthma medication usage. From 1997 to 2000 the mean number of prescriptions 
decreased most for the two younger age groups (0-4 years and 5-14 years old) and 
decreased a little for the 15-34 year old and 35-64 year old age groups. The mean 
number of prescriptions purchased decreased most for the 0-4 age group from 0.36 in 
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1997, to 0.03 in 2000. There was very little to no difference between males and females 
for all age groups in 2000. 
The mean number of inhaled ipratropium bromide prescription purchases did not 
increase appreciably from 1997 to 2000 for all age groups. There was very little 
difference between males and females groups except within the 35-64 year old group, 
wherein the mean for males was moderately greater than that for females. 
The mean number of long-acting beta2-agonist prescriptions increased very little 
for all except for the 35-64 year old group, which decreased from 1997 to 2000. There 
was also very little difference between males and females for all age groups except 
within the 35-64 year old group.  
The mean number of prescriptions purchased for the Nedocromil drug group 
decreased in 2000 from 1997 across all age groups except in the 0-4 year old group. The 
0-4 age group had zero prescriptions in 2000, as it did in 1997. There was very little to 
no difference between males and females for all age groups in 2000.  
The mean number of prescriptions purchased for the Ketotifen drug group 
decreased in 2000 from 1997 across all age groups except in the 15-34 year old group. 
The 15-34 age group had zero prescriptions in 2000, as it did in 1997. There was very 
little to no difference between males and females for all age groups in 2000. 
 
 4.1.11.5  Summary of mean number of prescriptions 
 In summary, there was a pattern of steady decline the in mean number of short-
acting inhaled beta2-agonist use across all ages, in both sexes over time.  Short-acting 
beta2-agonist prescriptions were highest in the two older age groups (15-34 years and 
35-64 years) for both sexes, with males having a consistently greater mean number of 
prescriptions than females.  There were few differences by sex for all the drug groups.  
Most sex differences were within the oldest group, 35-64 year olds, where there is 
generally more diversity in the population. 
The highest mean inhaled corticosteroid prescription use was among the 
youngest, 0-4 year olds, and the oldest, 35-64 year old age groups, in both males and 
females. 
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Most importantly, there was a trend over time for the mean number of short-
acting beta2-agonist prescriptions to decrease and for the mean number of inhaled 
corticosteroid prescriptions to increase.  This trend was most predominant in children. 
 
4.1.12  Characteristics of users by medication group in 2000 
To further explore the characteristics of users for the type of medication being 
prescribed, data from the final year of the study was analyzed. Significant differences 
between the proportion of medication purchased by male and female users in 2000 were 
found for several medication groups (Table 4-16).  More males purchased inhaled short-
acting beta2-agonists and theophyllines than females. More females than males 
purchased oral corticosteroids, long-acting beta2-agonists, inhaled ipratropium bromide 
and anti-leukotriene medications. 
 
Table 4-16  Distribution of persons with asthma who purchased specific asthma 
medication by sex and medication group, 2000 
Medication Total Male Female  
 % % % p value 
Short-acting β2 78.9 79.8 77.9 <0.001
Inhaled Corticosteroids  70.4 70.6 70.2 0.435
Oral Corticosteroids 18.0 16.8 19.2 <0.001
Oral β2 4.3 4.5 4.2 0.230
Theophyllines 
2.0 2.3 1.7 <0.001
Sodium Cromoglycates 1.0 1.0 1.0 0.734
Inhaled Ipratropium 
Bromide 6.9 6.2 7.6 <0.001
Long-acting β2 1.7 1.2 2.3 <0.001
Nedocromil 
0.4 0.4 0.4 0.939
Ketotifen 
0.1 0.1 0.1 0.525
Combined Medication 
(Fluticasone & 
Salmeterol) 0.8 0.7 0.9 0.049
Leukotrienes 3.1 2.7 3.5 <0.001
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There were very few significant differences between males and females in the 
purchase of specific medications in 2000.  While more males than females purchased 
oral corticosteroids in the 0-4 year old age group and inhaled corticosteroids in the 5-14 
year old age group, the pattern was reversed for the adult age groups. 
When medication groups were further stratified by age as well as sex, significant 
differences were found between male and female groups within some age groups (Table 
4-17).  The three dominant medication groups, for all ages and both sexes, were short-
acting inhaled beta2-adrenergic agonists, inhaled corticosteroids, and oral 
corticosteroids. 
There were no differences between the proportion of male and female users 
under 15 years of age in the short-acting inhaled beta2-agonist medication group. Short-
acting beta2-agonist medication was purchased more by persons in the 15-34 year old 
group than by those in any other age group. Males purchased significantly more beta2-
agonists in the 15-34 year and the 35-64 year old age groups. 
Inhaled corticosteroids were purchased most by 0-4 year olds (82.1%) and the 
least in the 15-34 year old group, particularly by males (57.9%). All age groups, except 
the 0-4 year old group, had significant differences between males and females. In the 5-
14 year old group, males purchased significantly more inhaled corticosteroids than 
females. In the two older age groups (15-34 year and 35-64 year olds), the medication 
was purchased more by females. 
Oral corticosteroids were purchased most frequently by the 0-4 year and 35-64 
year old age groups in 2000, both being just over 22.0%. Males and females were 
significantly different in all age groups, except in the 5-14 year old age group for oral 
corticosteroids. In the 0-4 year old group, males purchased more than females. In the 
two older groups (15-34 year and 35-64 year olds) females purchased more oral 
corticosteroids than males. 
Oral beta2-agonists were purchased most by the 0-4 year old group (15.2%). The 
proportion of males and females did not differ significantly in all age groups, except 
within the 5-14 year old group, wherein more females purchased the medication. 
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In 2000, there was no significant difference between males and females in any 
age group for those with asthma who purchased theophylline medication.  There were no 
significant differences between males and females for the medication group inhaled 
ipratropium bromide, except in the 15-34 year old group, wherein more females than 
males purchased the medication.  
 In 2000, the proportion of persons with asthma who purchased long-acting 
beta2-adrenergic agonists increased with successive age groups. Males and females 
differed only in the 0-4 year old and 35-64 year old groups, with more females than 
males having purchased the medication. 
For the drug groups Sodium Cromoglycates, Nedocromil, Ketotifen, and the 
combination drug containing Salmeterol and Fluticasone, in 2000 these drugs were used 
very little or not at all across all age groups. There were no significant differences 
between males and females for these medication groups.  
Anti-leukotrienes were purchased most by those in the 35-64 year old group 
(4.2%).  They were purchased least by those in the 0-4 year old group. There were 
significant differences between males and females in the two older age groups, with 
more females having purchased the medication than males. 
 
 4.1.12.1  Summary of characteristics of users by medication group in 2000 
In summary, the three dominant medication groups in the year 2000 were inhaled 
short-acting beta2-agonists, inhaled corticosteroids, and oral corticosteroids.  Males in 
the 15-34 year old age group were the most frequent users of short-acting beta2-agonist 
medication. Inhaled corticosteroids were purchased most by 0-4 year olds, and least by 
15-34 year old males.  In the two older age groups (15-34 year and 35-64 year olds), 
inhaled and oral corticosteroids were purchased most by females.  Oral corticosteroids 
were purchased most by the youngest and oldest age groups.  The 0-4 year old age group 
had the highest use of oral beta2-agonists, which did not include nebulized medication, at 
15.2%.  Long-acting beta2-agonists and anti-leukotriene medication were more often 
purchased by women, 35-64 years of age. 
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4.2  Research Question #2:   
What is the distribution of specific combinations of asthma medication use among 
persons with physician-diagnosed asthma by age and sex for the period of January 
1, 1991 to December 31, 2000. 
 
The CCG of 1996 and 1999 (4;11) provided information on recommended and 
potential combinations of medications suitable for asthma management. In conjunction 
with the guidelines, the data was examined for the frequency of use of specific 
combinations of medications over the ten years of the study.   
Several permutations were made to identify the most frequently purchased 
medication combinations.  The six most frequently identified combinations are presented 
in Table 4-18.  These combinations happened to coincide with those suggested by the 
CCG.  
Where the frequency, and contribution, of a combination was very small it was 
excluded from the analysis as a distinct combination and instead joined the group “All 
other medications” (used in combinations). In the final assessment, the “All other 
medications” category contained all the combinations of asthma medications not 
specified as being the top six most frequently purchased by persons using asthma 
medication. 
 
4.2.1  Proportion of users of asthma medication combinations by year 
Short-acting inhaled beta2-adrenergic agonist medication used alone had the 
largest proportion of purchasers from 1991 to 1993 (Table 4-18).  From 1994 to 2000, 
beta2-agonists were second most popular to the combination of inhaled short-acting 
beta2-agonists and inhaled corticosteroids to an increasing degree (as the combined 
medications increased in proportion and the single preparation received a decreasing 
share). 
Inhaled corticosteroids had only 3.9% of purchasers in 1991, but from 1992 to 
1996 this proportion increased to 13.8% to become the third largest group that year. 
From 1996 to 1998, the number of purchasers of inhaled corticosteroids dropped to 
12.0% in 1998. In 1999 and 2000, their number recovered to 13.2% in 2000. Overall, 
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purchasers of inhaled corticosteroids increased steadily over the ten year study period.  
The drug combination of inhaled short-acting beta2-adrenergic agonists and 
inhaled corticosteroids was the primary combination used in all years.  By 2000, 38.7% 
of users were purchasing this combination.  The drug combination of inhaled short-
acting beta2-adrenergic agonists, inhaled corticosteroids, and oral corticosteroids had 
4.1% purchasers in 1991. By 2000, this combination had doubled to 8.6%. 
The medication combination of short-acting inhaled beta2-adrenergic agonists, 
inhaled corticosteroids, and respiratory smooth muscle relaxants (including 
theophyllines), had a relatively low percentage of purchasers at the beginning of the 
study in 1991 with 3.4%.  The percentage for this combination gradually and steadily 
declined every year of the study period to 0.5% by the year 2000. 
The medication combination of inhaled short-acting beta2-adrenergic agonists, 
inhaled corticosteroids and unclassified therapeutic agents (including sodium 
cromoglycates) had 5.3% purchasers in 1991. By the end of the study period, 0.4% of 
asthma medication purchasers were using this combination of medications. 
A more popular combination of short-acting beta2-adrenergic agonists and 
smooth muscle relaxants had 11.4% of purchasers in 1991. The proportion of purchasers 
of this combination decreased sharply every year of the ten year period of the study to 
0.3% of purchasers in 2000.  The “All other medications” group accounted for about 
15.0% of users throughout the study period. 
 
4.2.2  Proportion of users of asthma medication combinations by age for 1991, 1994, 
1997, and 2000 
There was gradual change in the use of medication(s) over all ten years of the 
study that was shown to be far more dramatic when viewed using only four index years, 
1991, 1994, 1997 and 2000 (Figure 4-1 or Appendix D).  When a linear by linear test for 
trends was performed for the medication combinations for the selected four years, the 
result was significant at χ2 = 1905.35, df 1, p < 0.001.  Over the study period, the 
difference in the proportion of specific combinations use between males and females 
was minimal (Appendix B).
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While the proportional use of the preferred combination of inhaled short-acting 
beta2-adrenergic agonists and inhaled steroids increased in each age group over time, the 
most dramatic increases were seen for children in the 0-4 year old age group (Tables 4-
19 and 4-20).  In 1991, only 4.5% of the 0-4 year olds purchased this combination. 
Instead, most 0-4 year old combination drug users were purchasing short-acting beta2-
adrenergic agonists with unclassified agents (including sodium cromoglycates) at 28.3%.  
By 2000, 41.4% of 0-4 year olds, purchased the short-acting beta2-adrenergic agonist 
and inhaled corticosteroid combination.  The use of the inhaled short-acting beta2-
adrenergic agonists and unclassified agents combination was virtually undetectable. 
Children in the 5-14 year old group doubled their purchase of inhaled short-
acting beta2-adrenergic agonists with inhaled corticosteroids from 1991 to 2000.  They 
also reduced their use of inhaled short-acting beta2-adrenergic agonists with unclassified 
agents from 16.7% to 0.3%. 
There was an increase in the proportion of both 0-4 year old and 5-14 year old 
users in the purchase of the inhaled short-acting beta2-adrenergic agonists, inhaled 
corticosteroid, and oral corticosteroid combination.  From 1991 to 2000, the 0-4 year 
olds increased from 1.2% to 15.6%, and the 5-14 year olds increased from 2.2% to 7.7%. 
 
4.2.3  Summary of research question #2 
In summary, there was a change in the distribution of medication combinations 
from 1991 to 2000.  The use of short-acting beta2-agonist medication, used alone, 
decreased over time, while the use of inhaled corticosteroids (monotherapy) increased.  
Inhaled corticosteroids and inhaled short-acting beta2-agonists, in combination, 
increased from 20.0% in 1991 to 40.0% of medications dispensed in 2000.  Similarly, 
there was an increase in the combined use of inhaled corticosteroids, short-acting beta2-
agonists, and oral corticosteroids, which more than doubled from 4.0% in 1991 to 9.0% 
in 2000. 
Reductions in the use of both smooth muscle relaxants and unclassified agents, 
each in their respective combination with inhaled corticosteroids and short-acting beta2-
agonists, were observed over the study period.  The largest change in the use of inhaled 
corticosteroids and short-acting beta2-agonists in combination, was seen  
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Table 4-19  Proportion of drug treatment users by age group, 1991 and 1994 
 Age Groups 
 0-4yrs 5-14yrs 15-34yrs 35-64yrs 
Calendar year - 1991 
Medication(s) % % % % 
All other medications 
(used in combinations) 16.2 11.6 11.8 22.7
Short-acting β2-agonists (used alone in 
year) 38.9 33.1 43.4 23.8
Inhaled corticosteroids (used alone in 
year) 1.0 4.0 3.8 5.4
Short-acting β2-agonists + Inhaled 
corticosteroids 4.5 19.9 22.2 22.7
Short-acting β2-agonists + Inhaled 
corticosteroids + Oral corticosteroids 1.2 2.2 4.5 7.6
Short-acting β2-agonists + Inhaled 
corticosteroids + Smooth muscle 
relaxants 
0.4 1.2 3.4 7.9
Short-acting β2-agonists + Inhaled 
corticosteroids + Unclassified agents 6.1 9.4 2.8 2.6
Short-acting β2-agonists + Smooth 
muscle relaxants 3.4 2.0 3.1 5.0
Short-acting β2-agonists + Unclassified 
agents 28.3 16.7 5.0 2.2
TOTAL  2699 5719 5065 4608
Calendar year - 1994 
All other medications 
(used in combinations) 14.1 10.0 9.5 20.1
Short-acting β2-agonists (used alone in 
year) 28.1 24.6 37.0 21.8
Inhaled corticosteroids (used alone in 
year) 10.3 15.7 7.5 9.8
Short-acting β2-agonists + Inhaled 
corticosteroids 21.3 30.6 32.0 30.0
Short-acting β2-agonists + Inhaled 
corticosteroids + Oral corticosteroids 6.8 6.0 7.7 11.2
Short-acting β2-agonists + Inhaled 
corticosteroids + Smooth muscle 
relaxants 
0.2 0.3 1.5 3.2
Short-acting β2-agonists + Inhaled 
corticosteroids + Unclassified agents 6.7 5.8 1.5 1.3
Short-acting β2-agonists + Smooth 
muscle relaxants 0.4 0.3 0.7 1.6
Short-acting β2-agonists + Unclassified 
agents 12.1 6.8 2.4 1.1
TOTAL  2656 6357 6405 5413
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Table 4-20  Proportion of drug treatment users by age group, 1997 and 2000 
 Age Groups 
 0-4 5-14 15-34 35-64 
Calendar year - 1997 
Medication(s) % % % % 
All other medications 
(used in combinations) 12.5 7.1 8.3 21.4
Short-acting β2-agonists (used alone in 
year) 19.6 21.9 33.6 18.5
Inhaled corticosteroids (used alone in 
year) 14.9 20.1 8.6 11.1
Short-acting β2-agonists + Inhaled 
corticosteroids 34.9 37.3 38.5 34.9
Short-acting β2-agonists + Inhaled 
corticosteroids + Oral corticosteroids 9.8 7.5 7.5 9.8
Short-acting β2-agonists + Inhaled 
corticosteroids + Smooth muscle 
relaxants 
0.2 0.1 0.8 1.9
Short-acting β2-agonists + Inhaled 
corticosteroids + Unclassified agents 3.5 3.1 1.1 1.0
Short-acting β2-agonists + Smooth 
muscle relaxants 0.3 0.0 0.4 0.8
Short-acting β2-agonists + Unclassified 
agents 4.3 2.8 1.1 0.6
TOTAL  3022 6652 7090 6809
Calendar year - 2000 
All other medications 
(used in combinations) 11.4 10.2 11.9 24.4
Short-acting β2-agonists (used alone in 
year) 13.5 19.7 33.5 19.6
Inhaled corticosteroids (used alone in 
year) 17.3 18.5 8.2 11.7
Short-acting β2-agonists + Inhaled 
corticosteroids 41.4 42.8 38.5 34.2
Short-acting β2-agonists + Inhaled 
corticosteroids + Oral corticosteroids 15.6 7.7 6.8 8.3
Short-acting β2-agonists + Inhaled 
corticosteroids + Smooth muscle 
relaxants 
0.1 0.1 0.3 1.1
Short-acting β2-agonists + Inhaled 
corticosteroids + Unclassified agents 0.4 0.6 0.3 0.3
Short-acting β2-agonists + Smooth 
muscle relaxants 0.1 0.0 0.1 0.3
Short-acting β2-agonists + Unclassified 
agents 0.2 0.3 0.3 0.2
TOTAL  3100 6592 7600 7810
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between the years 1991 and 1994. 
 While the proportional use of the most preferred combination of inhaled short-
acting beta2-adrenergic agonists and inhaled corticosteroids increased over time in each 
age group, the most dramatic increases were seen in the 0-4 year age group.  There were 
no changes between males and females in the use of selected combinations during the 
study period. 
 
4.3  Research Question #3: 
What is the variation in the monthly age-sex specific, short-acting inhaled ß2-
adrenergic agonist and inhaled corticosteroid use for the years 1996 to 2000? 
 
In order to identify seasonal variation in the use of short-acting beta2-agonist and 
inhaled corticosteroid medication, data from the years 1996 to 2000 were examined.  As 
seen in Figures 4-2 and 4-3, there was limited variation between the years in the number 
of prescriptions purchased by month for either inhaled corticosteroids or short-acting 
beta2-agonists. 
From 1996 to 2000, within each year, the number of short-acting beta2-agonist 
prescriptions increased from around 5000 prescriptions at the beginning of the year to 
6000 prescriptions at the end of the year. All five years showed a similar pattern with a 
gradual increase in the number of prescriptions from January to December, and peak 
increases occurring in May, September and December (Figure 4-3).  There were also 
shared low points across the five years, in the months of February, July, and November.   
On a linear by linear test for trends for the year 2000, the result for trend by 
month was significant (χ2 =  25.97, df 1, p < 0.001), demonstrating that as time passed 
by month, the number of inhaled short-acting beta2-agonist prescriptions increased 
significantly.  Similar significant trends were found for 1999 (p < 0.001) and 1996 (p < 
0.001).  The lowest number of prescriptions in the year 2000 was 4460 (February) and 
the highest was 5978 (December). The lowest number of prescriptions of beta2-agonists 
in 1999 was 4872 (February) and the highest was 6621 (December). In 1996, the lowest 
number of prescriptions was 4753 in February, and the highest number was 6049 in 
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December.  Although similar patterns were seen for 1997 and 1998, the results of the 
linear by linear test for trends for those years were not significant. 
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Figure 4-2  Number of short-acting β2-agonist prescriptions purchased, 1996 to 2000 
 
From 1996 to 1998, within each year, the number of inhaled corticosteroids 
increased from around 3100 prescriptions at the beginning of the year to 4200 
prescriptions at the end of the year.  For the years 1999 and 2000, the number of inhaled 
corticosteroid prescriptions increased from around 3500 at the beginning of the year to 
5300 at the end of the year.  In all five years there was an increase from January to 
December, with peak increases occurring during the same months: May and June, 
September and October, and December.  The shared trough period was during July and 
August, with another small dip occurring in November. 
The year 1999 was significant in a linear by linear test for trends at (χ2 =  55.47, 
df  1, p < 0.001), meaning that inhaled corticosteroid prescriptions increased 
significantly over the year. Other years significant for the linear by linear test were: 
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1998 (χ2 =  12.10, df 1, p < 0.00); 1997 (χ2 =  10.38, df 1, p < 0.001); and, 1996 ( χ2  =  
45.46, df 1, p < 0.001). The only year that was not significant for the linear by linear test 
for trends was the year 2000, meaning that the number of prescriptions neither increased 
nor decreased significantly over the year. 
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Figure 4-3  Number of inhaled corticosteroid prescriptions purchased, 1996 to 2000 
 
 
4.3.1  Monthly distribution of short-acting β2-agonist prescriptions by age group and 
calendar year  
 The patterns of monthly use of short-acting inhaled beta2-agonists and inhaled 
corticosteroids, by age groups, were generally consistent over the five years that were 
chosen for review.  
 
 4.3.1.1  Short-acting β2-agonist prescriptions by age group and month, 1996 
Among all the age groups, the number of short-acting inhaled beta2-agonist 
prescriptions was highest in the 15-34 year old group (Figure 4-4).  
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Number of beta2-agonist prescriptions by age and month, 1996.
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Figure 4-4  Number of beta2-agonist prescriptions by age group and month, 1996 
 
The two older age groups shared a low in the number of prescriptions in 
February, followed by a steady increase to a peak in May.  The 15-34 year old group 
maintained this peak until October when there was a decrease in the number of 
prescriptions to December. The 35-64 year old group decreased their number of beta2-
agonist prescriptions after May to a low in September then the number was increased 
gradually to a final peak in December, the opposite direction of the 15-34 year old 
group. 
The peak increase for the 5-14 year olds occurred in September, with a smaller 
peak in May.  The peak increases for the 0-4 year old group were small by comparison, 
but seemed to occur in February and October.  The two younger age groups shared a dip 
in the number of β2-agonist prescriptions during the July and August period. 
All the age groups had significant results for the linear by linear test for trends. 
All the age groups, except the 0-4 year olds, appeared to increase in the number of short-
acting inhaled beta2-agonist prescriptions over the year. The linear by linear trends were 
as follows: 0-4 year old group: χ2 =  9.84, df 1, p < 0.01; 5-14 year old group: χ2 =  
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12.52, df 1, p < 0.001;  15-34 year old group: χ2 =  17.07, df 1, p < 0.001; and, 35-64 
year old group: χ2 =  27.74, df 1, p < 0.001. 
 
 4.3.1.2  Short-acting β2-agonist prescriptions by age group and month, 1997 
In 1997, the highest monthly use occurred with the 15–34 year old group, and the 
35-64 year old group.  The 0-4 year old group had the lowest number of prescriptions, 
between 270 (August) and 482 (April) (Figure 4-5). 
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 Figure 4-5  Number of beta2-agonist prescriptions by age group and month, 1997 
  
The 35-64 year old age group had significant results for the linear by linear test 
for trends (χ2 =  8.25, df 1, p < 0.01), indicating an increase in prescriptions over the 
year in 1997.  Where the 35-64 year old group had a dip in the number of beta2-agonist 
prescriptions, the 15-34 year olds had a peak. Other than this divergence, the two older 
age groups shared similar patterns of increase and decrease in the number of 
prescriptions. 
In 1997, the 5-14 year old age group had significant results for the linear by 
linear test for trends, χ2 =  17.61, df 1, p < 0.001, indicating an increase in prescriptions 
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over the year in 1997, as was the case in 1996. The 5-14 year old group had a large peak 
in the number of prescriptions in September that the 0-4 year old group did not.  Both 
groups had a dip in the number of prescriptions in July.  
 
 4.3.1.3  Short-acting β2-agonist prescriptions by age group and month, 1998 
Though the numbers of prescriptions between the two older groups were similar 
and in a much higher range than the two younger groups, it was shown in 1998, as not 
seen previously, that the 15-34 year old group shared a pattern of peak increases and 
decreases with the 5-14 year old group (Figure 4-6).  The peak increases for the 5-14 
year olds and the 15-34 year olds were in May and September.  The important summer 
trough was shared among all four age groups in 1998.  The 35-64 year old age group 
was the only group in 1998 with significant results for linear by linear test for trends, χ2 
=  7.80, df 1, p < 0.01, indicating an increase in beta2-agonist prescriptions. 
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Figure 4-6  Number of beta2-agonist prescriptions by age group and month, 1998 
 
 4.3.1.4  Short-acting β2-agonist prescriptions by age group and month, 1999 
All age groups, except for the 0-4 year olds, appeared to increase in the number 
of short-acting inhaled beta2-agonist prescriptions over the year (Figure 4-7). All of the 
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age groups had significant results for the linear by linear test for trends.  For the 0-4 year 
old group the linear by linear result was χ2 =  28.91, df 1, p < 0.001. For this group, the 
number of prescriptions appeared to decrease notably from March to August, and also 
greatly increase from August to December. For the 5-14 year old group the linear by 
linear result was χ2 =  8.78, df 1, p < 0.01.  The linear by linear result for the 15-34 year 
old group was χ2 = 12.14, df = 1, p < 0.001, and for the 35-64 year old group it was χ2 = 
41.31, df 1, p < 0.001.  As in 1998, the 5-14 year old group and the 15-34 year old group 
had similar patterns of peak increases and decreases during the year of 1999.   
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Figure 4-7  Number of beta2-agonist prescriptions by age group and month, 1999 
 
All four age groups shared a dip in July and August, but for the two older age 
groups it was a more subtle decrease.  September continued to be the most important 
month of increase in the number of prescriptions for the 5-14 year old age group.  
December was again, an important peak for the two older groups since 1997. 
 4.3.1.5  Short-acting β2-agonist prescriptions by age group and month, 2000 
In 2000, all four age groups seemed to share a pattern of peak increase in May 
followed by a drop in the number of beta2-agonist prescriptions in July (Figure 4-8).  
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The 5-14 year old and 15-34 year old groups showed peak increases in September.  All 
age groups except the 15-34 year olds showed an increase in prescriptions in December. 
The 35-64 year old age group had significant results for the linear by linear test for 
trends, χ2 = 21.58, df 1, p < 0.001, indicating an increase in prescriptions in 2000.  The 
15-34 year old age group also had significant results for the linear by linear test for 
trends, χ2 = 9.10, df 1, p < 0.01, which indicated an increase in the number of 
prescriptions over the year. 
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Figure 4-8  Number of beta2-agonist prescriptions by age group and month, 2000 
 
4.3.2  Monthly inhaled corticosteroid prescriptions by age group and calendar year 
 4.3.2.1  Inhaled corticosteroid prescriptions by age group and month, 1996 
Among all four age groups, the number of inhaled corticosteroid prescriptions 
was highest for the 35-64 year old group (Figure 4-9).  
 
 
 
70
Number of inhaled corticosteroids prescriptions by age and month, 1996.
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Figure 4-9  Number of inhaled corticosteroid prescriptions by age group and month, 
1996 
 
All four age groups appeared to have peak increases in May, followed by a sharp 
decrease in the number of inhaled corticosteroid prescriptions in July and August.  For 
the 15-34 year old age group the July decrease was subtle.  The 5-14 year old group had 
an increase in prescriptions in September, while for the 0-4 year and 15-34 year old 
groups this increase occurred in October.  For the 35-64 year old group, from the 
summer trough, there was a steady increase in the number of inhaled corticosteroid 
prescriptions to December. All age groups, except for the 5-14 year old age group, had 
significant results for the linear by linear test for trends (p < 0.001), indicating an 
increase in prescriptions over time. 
 
 4.3.2.2  Inhaled corticosteroid prescriptions by age group and month, 1997 
The age groups over five years old appeared to increase in their number of 
prescriptions over the year (Figure 4-10).  All the age groups, except the 15-34 year old 
group, shared a notable decrease in prescriptions in August.  The 35-64 year olds 
seemed to share a peak increase in prescriptions in June with the 5-14 year old group.  
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The two younger age groups showed an increase in prescriptions in September, though 
the peak was more extreme for the 5-14 year old group.  The most striking peak increase 
was for the 35-64 year old group in their number of inhaled corticosteroid prescriptions 
in December of 1997. All age groups, except for the 0-4 year old age group, had 
significant results for the linear by linear test for trends (p < 0.001). 
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Figure 4-10  Number of inhaled corticosteroid prescriptions by age group and month, 
1997 
 
 4.3.2.3  Inhaled corticosteroid prescriptions by age group and month, 1998 
In 1998 only one age group, the 35-64 year old group, had a significant result for 
the linear by linear test for trends, χ2 = 13.03, df 1, p < 0.01. All four age groups shared a 
low in the number of inhaled corticosteroid prescriptions in July and August followed by 
an increase in the fall (Figure 4-11).  The 5-14 year olds and 15-34 year old group also 
shared a peak increase in May.   The most notable peak for the 35-64 year old group 
remained that of December’s, but in 1998 there was a secondary peak in June. 
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Number of inhaled corticosteroid prescriptions by age and month, 1998.
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Figure 4-11  Number of inhaled corticosteroid prescriptions by age group and month, 
1998 
 
 4.3.2.4  Inhaled corticosteroid prescriptions by age group and month, 1999 
In 1999, the 0-4 year old age group and the 35-64 year old age group had 
significant results for the linear by linear test for trends (p < 0.001).  As in previous 
years, all four age groups shared a low in the number of inhaled corticosteroid 
prescriptions in July and August followed by an increase in the fall (Figure 4-12).  The 
peak increase in prescriptions in September was mainly shared between the 5-14 year 
old group and the 15-34 year old group.  In 1999, the three oldest groups had an increase 
in prescriptions in June, while the 0-4 year old group had an increase earlier in March.  
As seen previously, the most notable peak for the 35-64 year old group was in 
December. 
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Number of inhaled corticosteroid prescriptions by age and month, 1999.
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Figure 4-12  Number of inhaled corticosteroid prescriptions by age group and month, 
1999 
 
 4.3.2.5  Inhaled corticosteroid prescriptions by age group and month, 2000 
In 2000, only one age group, the 5-14 year old group, had a significant result for 
the linear by linear test for trends, χ2 = 10.61, df 1, p < 0.001.  All four age groups 
shared a low in the number of inhaled corticosteroid prescriptions in July increase in the 
fall (Figure 4-13).  Once again, the peak increase in prescriptions in September was 
mainly shared by the 5-14 year old and the 15-34 year old groups.  The three oldest 
groups, as in 1999, had an increase in prescriptions in June while the 0-4 year old group 
had an increase earlier in May (it was March in 1999).  As seen previously, the most 
notable peak for the 35-64 year old group was in December.  In 2000, it appeared that all 
four age groups increased in the number of inhaled corticosteroid prescriptions in 
December.   
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Number of inhaled corticosteroid prescriptions by age and month, 2000.
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Figure 4-13  Number of inhaled corticosteroid prescriptions by age group and month, 
2000 
 
4.3.3  Monthly distribution of β2-agonist prescriptions by sex and calendar year 
 For each of the five years, the difference between the numbers of short-acting 
beta2-agonist prescriptions for males and females was minimal, and remained around 
500 prescriptions.  Males and females shared the same pattern of increases and 
decreases, which was similar to that of the number of beta2-agonist prescriptions by age 
and month showing all years, 1996 to 2000 (Figure 4-2).  In all sex comparisons, males 
had a greater number of prescriptions for each month, for all years. 
 When short-acting inhaled beta2-agonist prescriptions were examined by age, 
sex, and month, it was found that 35-64 year old females had a greater number of 
prescriptions than males of this age group in all months, for all the years, from 1996 to 
2000 (except for February and August of 1998 when males had a few more prescriptions 
than females).  The 35-64 year old female group often had the greatest number of 
prescriptions of all age and sex groups during the year, except when superseded by the 
15-34 year old males.  The 15-35 year old male group had the greatest number of 
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prescriptions for every May and from the beginning of summer to the end of fall, from 
1996 to 2000. 
 
4.3.4  Monthly distribution of inhaled corticosteroid prescriptions by sex and calendar 
year 
 For each of the five years, the difference between the numbers of inhaled 
corticosteroid prescriptions for males and females was minimal and closer in number 
than those of beta2-agonist prescriptions.  Males and females shared the same pattern of 
increases and decreases as the number of inhaled corticosteroid prescriptions by age and 
month showing all years, 1996 to 2000 (Figure 4-3).   
In most comparisons by sex, males had a greater number of prescriptions, with 
the exception of the year 1998 when in July, females had 1556 prescriptions and males 
had 1549 prescriptions.  The 35-64 year old females were also found to consistently 
have the highest number of prescriptions of all sex and age groups, for all months, and 
all years from 1996 to 2000. 
  
4.3.5  Summary of research question #3 results 
In summary, there was little change between the five years in the patterns of each 
medication purchased by month for both inhaled short-acting beta2-agonists and inhaled 
corticosteroids, respectively.  There was peak use for inhaled beta2-agonists in the spring 
and fall in all years.  There was a decrease in the use of both medications during the 
summer months.  There was a marked increase for both short-acting beta2-agonists and 
inhaled corticosteroids in December.   
When monthly purchases of short-acting beta2-agonists were examined by age, 
there was an increase in September for the 5-14 year olds, and in December for the 35-
64 year olds.  These patterns were consistent for all years.   
There was a decrease in the purchase of inhaled corticosteroids in the summer 
months for the 5-14 year old group, and a marked increase in inhaled corticosteroid 
purchases by the 35-64 year old age group in December.  Again, these patterns were 
consistent for all years.  The largest decreases in inhaled corticosteroid prescriptions 
occurred in the summer, and in January for the 5-14 year and 35-64 year old age groups. 
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4.4  Summary of Results 
 
 The results of this thesis provide some important information regarding asthma 
prescription purchases by Saskatchewan residents from 1991 to 2000. 
Question 1 
• Over the ten years, the proportion of persons with asthma who purchased at least one 
asthma prescription increased slightly, but significantly. 
• There were more males with asthma, and more male users of asthma medications 
throughout the study period.  Male users increased to a lesser degree than female 
users from 1991 to 2000. 
• All age groups increased in the proportion of users between 1991 and 2000.  The 
highest increase in use over time was for the 0-4 year old age group (6.1%).  There 
was a particular decrease in the proportion of persons in all age groups in 1993. 
• Excluding the northern health region, there was little variation in the proportion of 
persons with asthma per region who purchased asthma medication, 75.3% to 79.6%.  
The northern health region had the lowest proportion of asthma medication users per 
health region (63.7%). 
• Over the ten years, the share of total yearly asthma prescriptions for the 5-14 year 
old group decreased 5.3%, and the 35-64 year old group increased 5.2%.  
• Of total asthma prescriptions, the 0-4 year old group purchased only a 10.0% share 
between age groups.  The 35-64 year old age group had the greatest share of total 
prescriptions (40.3%).  Not surprisingly, males had a greater share of total 
prescriptions between the sexes. 
• Mean prescription purchases of all asthma medications decreased from 1991 to 
2000.  The lowest mean prescriptions were among the 0-4 year, and 5-14 year old 
age groups.  The highest mean prescriptions were in the 35-64 year old groups. 
• Means decreased across all age groups and for both sexes over time.  The greatest 
sex differences were found within the 15-34 year and 35-64 year old age groups.  
Within each age group from 1991 to 2000, males had a higher mean number of 
prescriptions than females. 
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• Over the ten years, more users with asthma purchased inhaled short-acting beta2-
agonists, followed by inhaled corticosteroids, then oral corticosteroids.   
• There was a trend over time for the mean number of beta2-agonist prescriptions to 
decrease, and for the mean number of inhaled corticosteroid prescriptions to 
increase.  This trend was most notable in children. 
• There was a pattern of steady decline, across all ages and in both sexes, in mean 
short-acting beta2-agonist prescriptions over time.  Short-acting inhaled beta2-agonist 
mean prescriptions were highest in the two oldest age groups (15-34 years and 35-64 
years) for both sexes, with males having the consistently greater mean.   
• The highest mean inhaled corticosteroid prescription use was among the 0-4 year, 
and 35-64 year old groups, for both males and females. 
• Males in the 15-34 year old age group had the greatest proportion of short-acting 
inhaled beta2-agonist medication of all age/sex user groups in the year 2000.  They 
were also the lowest users of inhaled corticosteroid medication. 
• At the end of the study period, 0-4 year olds had the greatest proportion of inhaled 
corticosteroids.  In the two older age groups (15-34 year and 35-64 year olds), 
inhaled and oral corticosteroids had more female purchasers in 2000. 
• In 2000, the 0-4 year old age group had the largest proportion of users of oral beta2-
agonists (15.2%), a medication group that excluded the nebulized form of the 
medication. 
 
When specific combination therapies for asthma were examined, the following 
findings were observed: 
Question 2 
• Over the ten year period, the use of short-acting inhaled beta2-agonist medication 
(alone) decreased over time while the use of inhaled corticosteroids (alone) 
increased. 
• There was a two-fold increase in the combined use of inhaled corticosteroids and 
beta2-agonists from 1991 to 2000.  The greatest change in use of this combination 
occurred between 1991 and 1994. 
• The differences between males and females were minimal. 
 
 
78
• The 0-4 year old age group had the most dramatic increase in the inhaled 
corticosteroid and short-acting β2-agonist combination from 1991 to 2000. 
• There was a marked reduction in the use of smooth muscle relaxants and unclassified 
medications, each used in combination with inhaled corticosteroids and short-acting 
beta2-agonists by the end of 2000. 
 
When seasonal patterns of prescriptions for inhaled short-acting beta2-agonist 
and inhaled corticosteroid purchases from 1996 to 2000 were examined the following 
observations were made: 
Question 3 
• There was little change between the five years in the patterns of medication 
purchased by month for both inhaled short-acting beta2-agonists and inhaled 
corticosteroids. 
• There was a sharp decline in the number of prescriptions filled, for both medications, 
during the summer months and in mid-winter (January and February). 
• There was a marked increase in prescription filling for 5-14 year olds in September.  
For 35-64 year olds an increase occurred in December.  These patterns of purchase 
increases were consistent for all years examined. 
• There was no noticeable difference in the patterns of monthly purchasing of 
prescriptions for either beta2-agonists or inhaled corticosteroids between men and 
women. 
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5.  DISCUSSION 
 
 
The main objectives of this study were to describe the characteristics of persons 
with asthma in a general population who use asthma medications, the manner in which 
asthma medication is used, and the seasonal variation in the purchase of the most 
common asthma medications. 
 
5.1  Use of Asthma Medication by Persons with Asthma 
The first important finding in this study was that nearly 80% of persons 
diagnosed with asthma in Saskatchewan from 1991 to 2000 purchased at least one 
asthma medication.  Over time, the proportion of medication users increased gradually.  
The purchase of asthma-related drugs by asthmatics was reported by Senthilselvan for 
the years 1981 to 1990 in Saskatchewan, and in that period the proportion of purchasers 
rose from an average of 65.0%, for all age groups, to 75.0% (2).  Changes in 
recommended asthma medication, delivery systems, and attitudes toward 
pharmacological treatment of asthma, may be explanations for the continued steady 
increase in the proportion of persons with asthma using medication that was observed in 
this 1991 to 2000 study.  Improved education and dissemination of national guidelines  
for the treatment of asthma (first published in 1996) to healthcare workers, and persons 
with asthma, could also partially explain improved “appropriateness” in asthma 
treatment.  Just over 20 percent of persons who received an asthma diagnosis did not 
pursue a pharmacologic treatment regimen and could be presumed to be cases of very 
mild severity, or (more likely) of non-compliance.  Senthilselvan suggested that 
overcoding of asthma and low socioeconomic status, where purchasing of medication 
may be a problem, could explain the non-purchasing behaviour of some persons with 
asthma (2). 
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5.1.1  Asthma medication users by age 
Subjects were separated into four physiologically meaningful (i.e., 
homogeneous) age groups, and it was found that the oldest group (35-64 year olds) 
maintained the greatest proportion of medication purchasers for almost the entire ten 
year study period.  It was the youngest age group (0-4 year olds) that had the greatest 
increase in users over the ten year period with a rise of 6.1%.  This youngest age group 
had the greatest proportion of users in 2000 (Table 4-2).  This was later shown to be due 
to more users purchasing inhaled corticosteroid medication (as a monotherapy and/or in 
combination with short-acting beta2-agonists (Tables 4-19 and 4-20). 
In 1992, an article by Spitzer et al. raised alarm throughout the asthma 
community about the elevated risk of near-death and death related to the use of short-
acting beta2-agonists (17).  In Table 4-1 it was shown that although the population of 
persons with asthma continued to increase, in 1993 the proportion of persons who 
purchased asthma medication in that year decreased.  Again, in Table 4-2, it was shown 
that in 1993 in all age groups, except the 15-34 year old group, there was a small 
decrease in the proportion of medication users.  When the proportion of asthma 
medication users was stratified by region, a decrease in 1993 was not seen in this data 
(Table 4-4).   
A decrease in the mean number of prescriptions was seen for all medications, 
except inhaled and oral corticosteroids, over the ten year period (Table 4-11).  Events 
that may have influenced the decrease in the mean use of short-acting beta2-agonists 
include research from New Zealand that showed a relationship between increased beta2-
agonist use and death (44;45), the Spitzer et al. article of 1992, and the publication of 
Canadian national asthma treatment guidelines. 
 
5.1.2  Asthma medication users by sex 
In every year of the study period, male asthmatics had a greater proportion of 
purchasers; and male users maintained higher mean prescription purchases of asthma 
medications.  Toward the end of the study period, the differences between the sexes 
narrowed on both measures.  The mean numbers of prescriptions for medication users 15 
years and older were greater compared to users less than 15 years of age.  The mean 
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number of prescriptions per year was particularly high for the oldest age group (35-64 
years old). 
 
5.2  Asthma Medication Users and Their Mean Use of Single Preparations 
The overall mean number of asthma prescriptions for users with asthma 
decreased over the ten year period.  The three leading single medications used 
throughout the ten year period of this study were short-acting beta2-agonists, inhaled 
corticosteroids, and oral corticosteroids.  From 1991 to 2000, the proportion of persons 
purchasing inhaled corticosteroids increased, as did the mean number of inhaled 
corticosteroid prescriptions (Table 4-11).  The users and mean use of inhaled 
corticosteroids increased for all ages and both sexes, as seen in Tables 4-18 and 4-10.  
This finding is consistent with the CCG, which have recommended the progressively 
earlier introduction of inhaled corticosteroids with every new publication (4;11;12;46).  
However, current research suggests that fear and misunderstanding about the role and 
potential side effects of inhaled corticosteroids could be interfering with their use by 
asthmatic patients (47). 
 
5.2.1  Short-acting beta2-agonists 
The purchasing of only short-acting beta2-agonists persisted in the asthma 
population from 1991 to 2000, despite the CCG that recommended that this medication 
should only be used alone in very mild cases of asthma, or only occasionally, in 
adulthood (Figure 1-1) (11).  Although the proportion of persons using beta2-agonists 
alone did decrease slightly from 1991 to 2000 (79.7% to 78.9%, Table 4-11), it was still 
far too high to be in compliance with consensus guidelines.  By the year 2000, it seems 
unlikely that a quarter of the medication-purchasing asthma population, including those 
who did not purchase any asthma medication, had pre-clinical (or sub-clinical) to very 
mild asthma (4;11). 
Short-acting beta2-agonist mean prescriptions were greater for males in all age 
groups throughout the study period.  This result is supported by research by Schatz et al. 
who found that all males in their study (aged 2 to 64 years) had significantly greater 
mean beta2-agonist prescriptions than their female counterparts (p < 0.001) (48).  In the 
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current study, particularly high users in the year 2000 were the 15-34 year old males 
with 3.53 mean prescriptions and 35-64 year old males with 3.56 mean prescriptions 
(Table 4-15).  The mean overall prescription use of the 15-34 year old males in 2000 
was 5.44 (Table 4-9); of this number, 3.53 mean prescriptions (approximately 65.0% of 
this group’s total medications) were devoted to short-acting beta2-agonist medication 
use.  Schatz et al. also found high short-acting, beta2-agonist medication use with the 
highest mean prescriptions among males 14-22 years and 23-64 years old, 7.9 to 7.7 
mean prescriptions per year, respectively (48).  Blais et al. also found high inappropriate 
use of short-acting beta2-agonists among their adult male patients (29). 
Unlike the younger adult males, in this study, 35-64 years old males who also 
had high beta2-agonist use, had a relatively high mean number of inhaled corticosteroid 
prescriptions; 2.45 mean prescriptions in 2000, which accounted for approximately 
32.0% of the group’s total medications.  Both males and females in this oldest age group 
frequently used, and were high users of, all asthma medications in general (Table 4-15).  
Schatz et al. also saw increased medication dispensings in their oldest age group (23-64 
years) (48).  Females of this age group used more inhaled and oral corticosteroid 
medications than males; and males used more short-acting beta2-agonists than females 
(48). 
 
5.2.2  Inhaled corticosteroids 
The increases observed in inhaled corticosteroid users and numbers of mean 
prescriptions during the study period were congruent with that recommended as first-line 
therapy for asthma by the CCG.  The 0-4 year old age group’s mean prescription use in 
this study was increasingly dominated by inhaled corticosteroid medication (2.16 mean 
prescriptions representing approximately 53.0% of this group’s total medications) and 
less by short-acting beta2-agonist mean number of purchases (1.26 mean prescriptions 
representing approximately 30.0%) in the year 2000 (Table 4-15).  One possible 
explanation for better adherence to the CCG in the very young children in this study is in 
the increased interest and control parents, physicians, and other interested parties (for 
example, schools) have over persons under 15 years of age.  The increase in inhaled 
corticosteroid users in the 0-4 year group over time, may be explained by the availability 
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of improved, appropriate delivery devices (diskhalers, aerochambers) and/or the 
development of nebulized Budesonide in the later years of the study.  Prior to these 
developments it would have been difficult to administer inhaled corticosteroids to 
children less than five years of age. 
The 15-34 year old males had the lowest mean number of inhaled corticosteroid 
prescriptions, 1.42 (approximately 26.0% of the group’s total medications), in the year 
2000 (Table 4-15).   The 15-35 year old females had a similarly low mean number of 
inhaled corticosteroid prescriptions, but had a much lower mean number of beta2-agonist 
prescriptions compared to their male counterparts (Table 4-15).  Schatz et al. found that 
mean prescriptions for inhaled corticosteroids were lowest for their middle age group 
(14-22 year olds), though the mean prescriptions for males were significantly greater 
than those for females (p < 0.01) (48).   
Overall, the biggest users of inhaled corticosteroids, in proportion and mean 
number of prescriptions in this study, were the 35-64 year old group.  This is similar to 
the increased inhaled corticosteroids use found by Schatz et al. for the 23-64 year old 
age group (48).   
The length of time with the disease could be important in understanding the 
pattern of use by males and females in this study.  Lindberg et al. found in their study of 
asthma medication compliance in Swedish subjects that increasing age and female sex 
were significant factors in patients taking their prescribed medication (49).  However, 
Lindberg et al. also found that increasing length of the disease decreased the odds of 
patient compliance with their prescribed medication (49). 
 
5.2.3  Other medications 
The decreases in users and mean number of prescriptions for sodium 
cromoglycate and theophylline medications over time were also consistent with the 
CCG. New treatments such as anti-leukotrienes, the pre-combined medication 
(Fluticasone and Salmeterol), and long acting beta2-agonists were too “newly emerged” 
in the study period to be observed for their true role and impact on the asthma 
population in Saskatchewan.   
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Oral corticosteroids, the third most often purchased medication, were first used 
mainly in 0-4 year old children, but later established a hold in the oldest age group (35-
64 year olds).  Schatz et al. found that females in the 23-64 year old age group were 
more likely than men to require oral steroids (48).  Oral corticosteroids and long-acting 
beta2-agonists appeared to have been used as supportive medication, presumably (as 
CCG indicated) where asthma cases were resistant to treatment and/or disease severity 
increased for all ages(4).   
 
5.3  Asthma Medication Users of Preparations in Combination 
The largest change in the number of users of inhaled corticosteroids and short-
acting beta2-agonists, as can be seen in Figures 4-1 and 4-2, occurred between 1991 and 
1994 when the Spitzer et al. article was published (17).  It can be seen in Figures 4-3 and 
4-4, that there were gradual increases in both the inhaled corticosteroid monotherapy 
group and the short-acting beta2-agonists/inhaled corticosteroid combination group, with 
a corresponding decrease in the short-acting beta2-agonist monotherapy group, which 
continued to the end of the study period.  As these results are consistent with the CCG 
recommendations of both 1996 and 1999, it is postulated that physician and patient 
education were partly responsible for these changes despite the concern of the CACG 
that dissemination and implementation of the guidelines had not been wholly successful 
(4;12;46). 
Users of both the inhaled corticosteroids and inhaled short-acting beta2-agonists 
combination, and the inhaled corticosteroids, short-acting beta2-agonists, and oral 
corticosteroids combination doubled over the study period.  Users of inhaled 
corticosteroids (monotherapy) more than tripled from 1991 to 2000.  A short course of 
oral corticosteroids for very young children was recommended in the 1996 CCG for 
severe exacerbations, which may explain the increase in users from 1991 to 2000 (11).  
Again, these results of increased users of inhaled corticosteroids singly and in 
combination are reassuring.  These results do not contradict existing research that found 
under use of inhaled corticosteroids and over use of short-acting beta2-agonists (25), but 
they have provided a long-term view of an encouraging trend. 
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 A reduction in the use of smooth muscle relaxants and unclassified agents, each 
in respective combination with inhaled corticosteroids, and short-acting beta2-agonists, 
was in accordance with the CCG recommendations.   This may be taken as further 
evidence that dissemination and implementation of the guidelines occurred during the 
study period (4). 
While the proportional use of the inhaled short-acting beta2-adrenergic agonists, 
inhaled corticosteroids combination increased over time in all age groups, the largest 
increase was in the 0-4 year old group (see Appendix C).  Again, this may be due to the 
increased influence over this age group by parents who monitored their children’s 
treatment recommendations.  There were no changes between males and females in the 
use of selected combinations during the study period. 
 
5.4  Seasonal Variation of Prescription Purchases 
Between 1996 and 2000, short-acting beta2-agonist and inhaled corticosteroid 
medication monthly purchases were similar within medication type for each calendar 
year.  Purchases of both types of medications decreased every year during the summer 
months.  Similar results were also reported by Crighton et al. (32), Johnston et al.(33), 
and Fleming et al. (31) who encountered the same “summer trough” before an autumn 
peak in asthma exacerbations and/or hospital admissions.  As in the case of the current 
findings, the reported patterns appeared to be heavily influenced by children.  The peak 
purchase of beta2-agonists in the spring, fall, and winter from 1996 to 2000 is supported 
by existing research where large peaks have been reported in the autumn with minor 
peaks in December, January, and April (32).  Existing research has also shown age 
dependent results in seasonal asthma exacerbations, with children experiencing more 
episodes in September, and older subjects having increases with the approach of winter 
(31).  In this study there was a marked increase for both beta2-agonists and inhaled 
corticosteroids in December for the 35-64 year old age group.  This finding of a winter 
increase in prescriptions in older adults could be related to influenza occurrences, or it 
may be an artifact of prescription purchasing practices.  It is possible that prescription 
purchasers who have paid their prescription deductible for the year wished to take 
advantage of the province’s drug plan, which would pay for medications over the 
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deductible, before the beginning of a new year.  Purchasers may also have been 
motivated by private or alternative insurance provisions for prescription purchases that 
ended in December.  These incentives might help to explain the observation of lower 
prescription numbers in January of each examined year, relative to the preceding 
December. 
Short-acting beta2-agonist prescriptions increased in September for the 5-14 year 
old group.  Johnston et al. explored asthma exacerbations in Canadian school children 
and found decreased purchases of inhaled corticosteroids in the summer months for the 
5-15 year old group (33).  Researchers also found that children were using less controller 
medication prior to returning to school in the fall, and may have been subjected to an 
elevated risk of a viral-induced asthma exacerbation (33).  Since rhinoviruses have been 
shown to have some association with the fall asthma epidemic in children (33), it would 
seem prudent to begin prophylactic treatment earlier in the summer, before their return 
to school, to see if this measure can remedy the fall exposure. 
 
5.5  Study Strengths 
This study was different from previous research in asthma pharmacological 
treatment because it drew from a combined patient and prescription database for the 
province of Saskatchewan that included almost every member of the population who 
received an asthma diagnosis, and then purchased a pharmacological treatment for that 
condition.  A study of this scale would not be possible by means of a self-report survey 
method, for example, as accuracy and response rate would be greatly decreased.  In 
addition, because Saskatchewan Health provided this study with pseudo-numbers to 
identify individuals, it was possible to calculate the mean use of medications by 
individuals over the ten year study period. This was a significant improvement over 
previous (ecological) research. 
The assumption tentatively used in this study is that the frequency with which 
one fills prescriptions is a proxy variable for both use and severity. Because short-acting 
beta2-agonist medications are inexpensive, it is possible that asthma patients purchased 
them just to have them on-hand, thereby inflating the appearance of beta2-agonist 
medication overuse.  Supporting this assumption are the four years of elevated beta2-
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agonist prescriptions found each December, which were followed by four comparatively 
low prescription numbers in January. 
Having ten years of data provided a heightened level of assurance that the 
observed trends and patterns in asthma care and treatment in Saskatchewan were 
genuine.  The extended period, and provision of individual data, allowed for a level of 
scrutiny that has not yet been fully explored. 
 
5.6  Study Limitations 
Descriptive studies are designed to “…describe the existing distribution of 
variables, without regard to causal or other hypotheses.” (50)  They are often used to 
analyze registry data, measure risks, and generate hypotheses.  As these studies are 
frequently retrospective, certain biases and limitations inject variability into the collected 
data.  These may include one or more of the following: diagnostic shift (the disease is 
diagnosed by evolving criteria over time); a change in the units of measurement in the 
diagnosis and/or treatment of the disease over time or a change in diagnostic tests over 
time.  
As the physician-billing database was used to determine the prevalence of 
asthma (using the ICD-9 three-digit code), the primary function of the database was 
physician remuneration, and the potential for a misclassification bias was present.  
Though an asthma related medication purchase was used to validate the diagnosis, the 
possibility of a bias persists as similar conditions require similar pharmacologic 
treatments (e.g., chronic obstructive pulmonary disease and short-acting beta2-agonists 
for first-line treatment) (51).   
The most important limitation of this study was that the prescription purchase 
does not connote the actual use of the medication.  Further, it does not ensure 
appropriate delivery of the medication is being practiced.   
In this study’s analyses, not all users/purchasers could be considered the same 
users for each year of this study, and therefore the results did not reflect individual 
change but rather, population change.  As such, we were unable to discern if, for 
example, the greatest short-acting beta2-agonist users were indeed the most severe 
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asthmatics.  With the addition of the hospitalization data to which this study’s data is 
linked, our understanding of asthma severity in Saskatchewan will improve. 
As mentioned previously, it is not possible to discern if the CCG influenced the 
changes in the purchasing behaviour of the asthma population and/or the behaviour of 
parents, educators, and physicians who care for asthmatic patients.  The results of these 
ten years of data imply that the CCG have made a real impact. 
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6.  RECOMMENDATIONS FOR FUTURE RESEARCH 
 
 
As a descriptive epidemiologic study, there are countless opportunities to 
generate new hypotheses and research from this study.  The surveillance of those who 
consume asthma medications and the manner in which they use their medications should 
continue, with particular focus on short-acting beta2-agonists, inhaled corticosteroids, 
and new emerging medications, such as anti-leukotrienes.   
This thesis study showed that the proportion of users and their mean number of 
short-acting beta2-agonist prescriptions were much higher than acceptable, according to 
national guidelines.  Monitoring of the continued decrease in both of these measures 
could serve as both an indication that the disease is reaching a suitable level of control 
(and severity is decreasing), and that the CCG are having an impact on asthma 
treatment.  Complimentary surveillance of the increase in inhaled corticosteroid users 
and their mean number of prescriptions would also support an impression of improved 
asthma control. 
Short-acting beta2-agonist users and mean number of prescriptions were 
particularly high among 15-34 year old males, and all 35-64 year old adults.  Further 
study of high risk and/or low-compliance groups would be warranted.  To address the 
issue of the large population of short-acting beta2-agonist monotherapy users, it may be 
useful to study special groups such as occasional users, and exercise induced users.  In 
addition, some means of understanding pre- and post-deductible prescription filling in 
Saskatchewan may be helpful in adjusting a potentially inflated number of certain 
medication purchases. 
The elevated use of oral beta2-agonist medication in the last year of the study 
was of concern, particularly for the 0-4 year old age group, as this medication group did 
not include a nebulized route of delivery.  Future research may wish to investigate 
reasons for this unexpected finding. 
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Validation of the relationship between the purchase of asthma medications and 
actual use is an enduring problem that requires further research.  Thus far, self-reported 
use of medications is often biased and insufficient as a measure of patient compliance 
(48;49).  Length of time since the onset of the disease may be a factor in determining 
patient compliance (48;49).  A longitudinal study of medication use that follows patients 
from their initial diagnosis of asthma into adulthood could add new information to the 
understanding of patient compliance. 
In future research regarding the seasonal variation of asthma exacerbations in 
school children, it might be useful to apply a case-control model to the problem, 
following through on recommendation of existing research (33).  As increased exposure 
to rhino-viruses is suspected in combination with observed summer decreases in asthma 
medication, cases could begin their prophylactic inhaled corticosteroid treatment before 
returning to school.  The controls in the trial would continue to refrain from taking their 
inhaled corticosteroid medication as usual. 
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APPENDIX D 
PROPORTION OF PURCHASERS BY MEDICATION TREATMENT, 1991, 1994, 
1997, AND 2000. 
 
Proportion of users by drug treatment (combinations) in 1991.
15%
35%
4%
20%
4%
3%
5%
3%
11%
OTHER
SBA
ICS
SBA + ICS
SBA + ICS + OCS
SBA + ICS + SPAS
SBA + ICS + UNCL
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Proportion of users by drug treatment (combinations) in 1994.
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Proportion of users by drug treatment (combination) in 1997.
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Proportion of users by drug treatment (combination) in 2000.
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